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RESUMO 
 
 As células ganglionares da retina (CG) têm um papel fundamental no 
processamento da informação até ao córtex visual, conforme evidenciam as suas 
características específicas morfológicas e funcionais. A lesão das CG constitui a base da 
patogénese de algumas doenças da retina e do nervo óptico. Assim, esta tese centra-se 
na identificação de novos biomarcadores de lesão em doenças adquiridas e genéticas das 
CG, nomeadamente na Neuropatia Óptica Glaucomatosa e na Neuropatia Óptica 
Hereditária de Leber (NOHL). 
 Deste modo, aplicámos um conjunto de métodos funcionais e estruturais, 
inovadores e convencionais, com o objectivo de comparar mecanismos patofisiológicos 
de lesão em dois grupos diferentes de pacientes, correspondendo a dois modelos de 
doença das CG: 1) modelo de neuropatia óptica hereditária, 15 portadores 
assintomáticos de NOHL com mutação mtDNA 11778G>A, pertencentes a duas 
gerações do mesmo pedigree; 2) modelo de neuropatia óptica adquirida, 52 
participantes provindos da consulta de Glaucoma, divididos nos seguintes grupos: 
hipertensão ocular (n=18 olhos), suspeitos de glaucoma (n=15 olhos) e glaucoma 
primário de ângulo aberto (n=19 olhos). Os dados obtidos foram comparados com dois 
grupos de controlos ajustados à idade e ao género. 
 Relativamente aos portadores assintomáticos de NOHL, fenotipámos a lesão 
subclínica em termos psicofísicos, neurofisiológicos e estruturais, através da 
sensibilidade ao contraste cromático (Cambridge Color Test, CCT), do 
electroretinograma pattern (ERG pattern, para medição da função das CG) e da 
tomografia de coerência óptica (OCT, para registo das espessuras da zona macular, da 
camada de fibras nervosas da retina e das camadas interna/externa da retina), 
respectivamente. Com o intuito de estabelecer uma relação entre as características do 
dano das CG e a reorganização cortical das áreas visuais corticais mapeadas 
retinotopicamente, foi usada a ressonância magnética estrutural em regiões de interesse 
mapeadas através da ressonância magnética funcional retinotópica. 
 Observou-se que a espessura da camada de fibras nervosas macular é predictiva 
de um mecanismo compensatório de plasticidade cortical nas áreas visuais corticais 
extraestriadas. Este foi também o parâmetro mais discriminativo entre portadores de 
NOHL e controlos, evidenciado pela análise da curva ROC. Assim, concluímos que a 
 xxii 
 
patologia dos axónios da CG pode desencadear plasticidade cortical compensatória nas 
áreas visuais extraestriadas V2/V3.  
 No que respeita aos indivíduos com Glaucoma, utilizámos métodos quantitativos 
psicofísicos, como a perimetria de dupla frequência (FDT) e CCT, para caracterizar o 
desempenhos das vias magno, parvo e coniocelulares. A função das CG foi registada 
pelo ERG pattern e a espessura da camada de fibras nervosas foi obtida através do 
OCT. Foram desenvolvidos três testes psicofísicos utilizando uma estratégia de resposta 
forçada com duas alternativas (variáveis independentes: movimento, sensibilidade ao 
contraste acromático e sensibilidade ao contraste cromático das três populações de 
cones L, M e S) tendo sido aplicados num subgrupo destes pacientes (16 com 
hipertensão ocular, 15 suspeitos de glaucoma e 12 com glaucoma primário de ângulo 
aberto). 
 Encontrámos disfunção relativa das vias retinocorticais magno, parvo e 
coniocelulares, desde o estadio inicial da doença. A sensibilidade ao contraste 
acromático encontrava-se alterada em pacientes com hipertensão ocular e as 
sensibilidades cromáticas estavam significativamente aumentadas nos eixos protan, 
deutan e tritan. A cerca de 80% de especificidade, o FDT foi o teste que apresentou a 
melhor sensibilidade para detectar o dano funcional precoce. Não obstante, a 
sensibilidade dos testes comerciais foi inferior quando comparada com os resultados dos 
nossos novos métodos psicofísicos, sugerindo que um teste com um menor grau de 
redundância apresenta uma maior capacidade para detectar precocemente danos 
glaucomatosos. Por fim, todos estes testes podem ser usados combinadamente como 
potenciais biomarcadores de progressão de doença, dado que os seus parâmetros se 
encontram moderadamente correlacionados com a história natural do glaucoma.   
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SUMMARY 
 
Retinal ganglion cells (RGC) are key players in the processing of visual 
information to the visual cortex, as further illustrated by their specific morphological 
and functional features. Degeneration of RGC is currently thought to play a key role in 
the pathogenesis of some retinal and optic nerve pathologies. So, the major focus of this 
thesis concerns the identification of novel biomarkers of impairment in acquired and 
genetic diseases of the RGC, namely glaucomatous optic neuropathy and Leber 
hereditary optic neuropathy (LHON). 
For this purpose we applied a range of novel and conventional functional and 
structural methods in order to compare pathophysiological mechanisms of damage in 
two different groups of patients, corresponding to two different models of the RGC 
impairment: 1) inherited optic neuropathy model, 15 asymptomatic LHON carriers 
(mtDNA 11778G>A point mutation) from two generations of the same pedigree; 2) 
acquired optic neuropathy model, 52 participants recruited from the glaucoma 
consultation, which were divided into different groups: ocular hypertension (HT, n=18 
eyes), glaucoma suspects (n=15 eyes) and primary open-angle glaucoma (n=19 eyes). 
Obtained data were compared with two distinct gender and age-matched groups of 
controls. 
Concerning asymptomatic LHON carriers, we phenotyped pre-clinical silent 
degeneration from the psychophysical, neurophysiological and structural points of view, 
using chromatic contrast sensitivity test (Cambridge Color Test, CCT), pattern 
electroretinogram (PERG; to measure RGC function) and optical coherence tomography 
(OCT; assessing macular, retinal nerve fiber layer/RNFL and inner/outer retinal layer 
thicknesses), respectively. In order to establish a link between features of RGC 
impairment and cortical reorganization of retinotopically mapped visual cortical areas, 
we also used structural magnetic resonance in regions of interest mapped using 
retinotopic functional magnetic resonance imaging (fMRI). 
We found that compensatory cortical plasticity occurring in extrastriate visual 
cortical areas is predicted by macular RNFL thickness. This was also the most 
discriminative measure between LHON carriers and controls, as revealed by Receiver 
Operating Characteristic (ROC) curve analysis. We conclude that pathology in RGC 
axons may trigger cortical compensatory plasticity in extrastriate visual areas V2/V3. 
 xxiv 
 
Concerning glaucoma patients, quantitative psychophysical methods, as 
Frequency Doubling Technology (FDT) and CCT, were used to assess magno, parvo 
and koniocellular pathways. RGC function was assessed by PERG and RNFL thickness 
was obtained using OCT. Three novel two-alternative-forced-choice (2AFC) 
psychophysical discrimination tests (independent variables: motion, achromatic and 
chromatic L, M and S cone contrast sensitivities) were developed by our group, 
implemented in relatively standard hardware and then applied to a subgroup of 
glaucoma patients (16 ocular hypertension, 15 glaucoma suspects and 12 primary open-
angle glaucoma). 
 We found a relative damage of magno, parvo and koniocellular retinocortical 
pathways since the initial stage of the disease. Mean achromatic contrast sensitivity 
(FDT) was impaired in patients with HT and chromatic thresholds were significantly 
increased for protan, deutan and tritan axes. At approximately 80% specificity, the FDT 
showed the highest sensitivity to detect early functional damage. Interestingly, the 
sensitivity of the currently available tests used is this study is lower comparing with our 
novel psychophysical discrimination tools, suggesting that a smaller degree of test 
redundancy leads to a great ability to detect early glaucomatous damage. Finally, all 
these tests can be used in combination as potential markers of disease progression, since 
their measures correlate moderately with the natural course of glaucoma. 
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AIMS 
 
This thesis is focused on the identification of novel biomarkers of 
pathophysiological impairment in acquired and genetic diseases of the retinal ganglion 
cells (RGC), namely glaucomatous optic neuropathy and Leber hereditary optic 
neuropathy (LHON).  
According to this global aim, we developed three novel psychophysical 
discrimination tests in order to functionally isolate specific and sparse RGC 
populations, without the redundancy afforded by the neighboring cells and possibly 
allowing an early diagnosis. Thus, we used two separated small and peripheral moving 
dots to probe motion sensitivity, achromatic and chromatic L, M and S cone contrast 
sensitivities. These tests were applied across several disease stages with the goal of 
obtaining new insights about the natural history of glaucoma.  
This strategy arose from the evidence that the conventional perimetry used in the 
clinical practice seems to be not sensitive enough to detect early RGC dysfunction. We 
argue that this is due to the fact that the stimulation approach (white targets) is 
simultaneously detected by all neurophysiological sub-systems in the retina.  
We also aimed to evaluate the potential ability of these novel tests to probe 
disease progression. 
In glaucomatous patients, and for comparison purposes, we also applied a broad 
range of psychophysical and electrophysiological tests. This further allowed to study 
independent visual information processing within magno, parvo and koniocellular 
pathways. We compared the diagnostic accuracy of the three novel psychophysical tools 
with some currently available tests described as sensitive to detect glaucoma at an early 
stage.  
Another goal of this work was to phenotype pre-clinical retinal degeneration of 
LHON mutation carriers from the psychophysical, electrophysiological and structural 
points of view. This allowed to compare phenotypic measures in another model of RGC 
degeneration. Using functional magnetic resonance imaging (fMRI), we further aimed 
to establish a link between features of RGC impairment and cortical reorganization in 
genotyped LHON carriers, as assessed by cortical thickness measures in retinotopically 
mapped visual cortical areas. 
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The first part of this thesis starts with a theoretical background in Chapter 1, 
which covers relevant basic topics that are important within the goals of this thesis, such 
as parallel information processing in vision, namely within the retina, the organization 
of subcortical (magno, parvo and koniocellular) and cortical (dorsal and ventral) visual 
pathways, and also aging of the visual pathway.  
Chapter 2 presents a specific introduction to the clinical models of RGC 
dysfunction addressed in this thesis. The first section refers to LHON and the second 
one refers to glaucomatous optic neuropathy. 
Chapter 3 describes the psychophysical, electrophysiological and structural 
methods used in the experimental work.  
The results obtained from the analysis of data are presented in Chapter 4, 5 and 
6, wherein the first data corresponds to the LHON model and the data of the last two 
chapters corresponds to the glaucoma model.  
Chapter 7 presents the discussion and final conclusions of the thesis.  
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CHAPTER 1 
 
PARALLEL PROCESSING IN VISION 
 
 
1.1.  BIOLOGY OF THE RETINA 
 
The first comprehensive anatomic description of the neural cell types that 
constitute the retina was revealed in the 19th century by Ramon y Cajal (Ramon y 
Cajal, 1892) and still remains largely correct. More recent applications of intracellular 
recording and staining techniques provided a detailed account of the neural architecture 
of the retina (Werblin and Dowling, 1969), which is organized in ten distinct layers of 
cells and their synapses, namely:  
1) Inner limiting membrane (vitreoretinal interface; basement membrane 
composed by Müller cells); 
2) Nerve fiber  layer (ganglion cell axons); 
3) Ganglion cell layer (nuclei of ganglion cells); 
4) Inner plexiform layer (synapses between bipolar cell axons and dendrites of 
ganglion cells and amacrine cells); 
5) Inner nuclear layer (nuclei of bipolar cells); 
6) Outer plexiform layer (synapses between photoreceptors axons and dendrites 
of bipolar cells); 
7) Outer nuclear layer (nuclei of rods and cones); 
8) Outer limiting membrane (layer that separates the inner segment of the 
photoreceptors from their cell nucleus); 
9) Photoreceptors layer (rods and cones); 
10) Retinal pigment epithelium (single layer of cuboidal cells).  
 
These can be simplified into 3 main processing stages. In fact, the neural 
architecture comprises a three-neuron excitatory pathway composed of 1) 
photoreceptors that transduce the light stimulus and 2) bipolar interneurons that relay 
the photoreceptor signals to 3) ganglion cells, the output neurons of the retina. Added to 
Pathophysiological mechanisms and novel biomarkers in acquired and genetic diseases of the RGC 
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this pathway are two sets of inhibitory interneurons: the horizontal cells that modify 
transfer at the photoreceptor-bipolar synapse and the amacrine cells that modulate 
information processing at the bipolar-ganglion cell synapse (Dacey, 2000) (Figure 1.1). 
 
 
 
Figure 1.1. Vertical cross-section of the retina. Note the principal cell types involved in visual 
information processing. RPE – retinal pigment epithelium; ONL – outer nuclear layer; OPL – outer 
plexiform layer; INL – inner nuclear layer; IPL – inner plexiform layer; GCL – ganglion cell layer 
(Adapted from Archibald et al., 2009). 
 
 
The human retina contains, on average, 128 million photoreceptors (Sekuler and 
Blake, 1994): 120 million of them are rods and the other 8 million are three types of 
cones, which are classified based on the peak wavelength within the visible spectrum to 
which their photopigment is highly sensitive [L-cones or sensitive to long-wavelengths 
(peak sensitivity at ~565 nm); M-cones or sensitive to middle-wavelengths (~535 nm); 
and S-cones or sensitive to short-wavelengths (~440 nm)] (Gegenfurtner and Kiper, 
2003). The cones respond to bright-light (photopic vision) and mediate high-resolution 
color vision. On the other hand, at low levels of light (scotopic vision), only the rods are 
activated. Thus, rods are important to monochromatic, low-resolution vision under very 
low levels of illumination. Under mesopic levels of light, both rods and cones are 
activated (Archibald et al., 2009). 
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The spatial arrangement of the photoreceptors is called ‘photoreceptor mosaic’. 
These neurons do not have a homogenous distribution across the retina (Curcio et al., 
1990; Ahnelt, 1998). In the center of the fovea (foveal pit), there are only cones (Figure 
1.2). In fact, this is the region of the retina with the highest density of cones. These 
cones are thinner and longer than cones of the surrounding retina, possibly because (in 
evolutionary terms) they need to absorb the incident photons of light more efficiently, 
contributing for a higher performance in visual acuity. The number of cones per area 
falls rapidly outside the fovea to a fairly even density into the peripheral retina (Curcio 
et al., 1987). Concerning rods, the first ones emerge at about 0.13 mm from the center 
of the fovea and their number increases rapidly, reaching a peak in a ring around the 
fovea at about 4.5 mm (18 degrees) from the foveal pit. In more peripheral regions the 
number of rods decreases, being always higher than the number of cones. Interestingly, 
the optic nerve is composed of about one million axons and since there are no 
photoreceptors, visual stimulation cannot occur (“blind spot”). 
 
 
 
Figure 1.2. The photoreceptors (rods and cones) distribution within the human retina (Adapted from 
Osterberg, 1935; Source: http://webvision.med.utah.edu/). 
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In summary, the light photons pass through the whole retina and are detected by 
photoreceptors. In the photoreceptors layer visual processing sets off with the 
transduction of light into bioelectrical signals. Then, photoreceptors transmit 
information to bipolar cells that in turn connect to ganglion cells. Finally, ganglion cells 
project their axons to form the optic nerve and convey visual information to the brain.  
 
 
 
1.1.1 THE RETINAL GANGLION CELL 
 
Ganglion cell axons travel from the retina to the lateral geniculate nucleus 
(LGN) and then to different parts of the visual cortex. The primate retina contains 20 or 
more types of morphologically and functionally distinct ganglion cells (Kolb et al., 
1992; Shabana et al., 2003). Nevertheless, in vitro preparations of primate retina 
provided information about three major types of ganglion cells that project to the LGN 
(Dacey, 1994; Kaplan, 2004): the parasol (Pα), midget (Pβ) and small bistratified cells.  
The parasol cells (about 10% of the ganglion cells) have larger dendritic fields 
and the corresponding axons are thicker (with more myelin) and have faster conduction 
time than the midget cells (about 80% of the ganglion cells) at any given eccentricity 
(Shabana et al., 2003; Yoonessi and Yoonessi, 2011) (Figure 1.3). The small bistratified 
ganglion cells tend to have larger dendritic field than the midget cells and smaller than 
the parasol cells (Yamada et al., 1996). For all types of cells, the RGC size correlates 
with the eccentricity (Perry et al., 1984; Shabana et al., 2003). 
The distribution of ganglion cells is very non-linear. In the perifoveal macula 
these cells are concentrated, becoming relatively sparse in the periphery. On the other 
hand, ganglion cells near the fovea tend to be smaller with smaller dendritic fields and 
axons, whereas some larger ganglion cells are mainly found peripherally (Carelli et al., 
2004). 
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Figure 1.3. The major ganglion cell types of a primate retina. At approximately the same eccentricity 
within the retina, the dendritic tree of the midget ganglion cell is smaller and denser than the parasol cell. 
Note that for both types of cells, the absolute size of the dendritic field increases with eccentricity 
(Adapted from Watanabe and Rodieck, 1989; Source: https://www.stanford.edu/group/vista/cgi-
bin/FOV/). 
 
 
Perry et al. (1984), using retrograde horseradish peroxidase labeling, found that 
the majority of Pα cells in the retina project to the magnocellular layers of the LGN 
(first two layers), whereas the majority of Pβ cells in the retina project to the 
parvocellular layers of the LGN (layers 3 to 6). Thus, it has become a common practice 
to refer to the RGC by their connections to the LGN, namely, parasol as magnocellular 
(M) cells and midget as parvocellular (P) cells (Shabana et al., 2003). In addition, there 
is some evidence that the small bistratified cells, project to interlaminar layers - 
koniocellular (K) layers, in parallel with the parasol and midget cells in the LGN 
(Kaplan, 2004; Yoonessi and Yoonessi, 2011). 
There are considerable differences in the physiological properties of M and P 
cells. The M cells have higher contrast sensitivity (CS) than P cells. Furthermore, the 
conduction time of the M pathway is faster than the P pathway (Yoonessi and Yoonessi, 
2011) and the time of response in the M cell tends to be transient, whereas the P cells 
respond in a sustained mode (Hicks et al., 1983).  
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1.2. MAGNO, PARVO AND KONIOCELLULAR SUBCORTICAL 
VISUAL PATHWAYS 
 
Anatomical and physiological measurements suggest that magno, parvo and 
koniocellular pathways carry different types of information to the brain. 
The M cells collect information from all types of cones, thus process no specific 
information about color and therefore detect “luminance”. These cells can also signal 
motion and are sensitive to high temporal/ low spatial frequency stimuli (Yoonessi and 
Yoonessi, 2011). On the other hand, the P cells are sensitive to low temporal and high 
spatial frequencies (Derrington and Lennie, 1984) and also mediate visual acuity, 
pattern and texture discrimination, besides chromatic information (P cells are sensitive 
to red-green opponency) (Schiller et al., 1991; Lynch et al., 1992; Kaplan, 2004). 
However, blue-yellow opponency is mediated by the small-bistratified ganglion cells 
(Dacey and Lee, 1994; Dacey, 2000). 
Some behavioral studies of monkeys developed by Schiller et al. (1990) showed 
that lesions of the P layers of LGN result in marked decreases in spatial CS, fine 
stereopsis, and pattern, color, texture and shape discrimination. These functions were 
unaffected by lesions of the M layers. In comparison, lesions of the M layers caused 
specific decreases in flicker (especially at high temporal frequencies) and motion 
sensitivity.   
 
 
 
1.3. DORSAL AND VENTRAL CORTICAL VISUAL PATHWAYS 
 
The axons from the M layers of the LGN project to the lamina 4C-α of the 
primary (striate) visual cortex (V1), while the axons from P layers project to layer 4C-β 
(Perry et al., 1984). Thus, the M and P visual pathways from the retina to the LGN 
remain clearly separated up to the level of V1 (Shabana et al., 2003). At the cortical 
level, two pathways dominate the complex network of connections in the visual cortex: 
the dorsal and ventral visual pathways. The dorsal pathway, which receives a major 
contribution from the M pathway, proceeds from V1 to the thick stripe regions of V2, 
mainly to the middle temporal (MT) area (specialized in motion processing) and to 
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areas in the posterior parietal cortex. On the other hand, the ventral pathway, which 
receives a major contribution from the P pathway, proceeds from V1 to the thin and 
interstripe regions of V2, mainly to V4 (specialized in color processing) and to areas of 
the inferotemporal cortex (Merigan and Maunsell, 1993; Shabana et al., 2003) (Figure 
1.4). 
 
 
 
Figure 1.4. Schematic diagram of visual pathways. The main subcortical visual pathways (Magno, Parvo 
and Koniocellular) proceed from the respective RGC and show a clean separation up to the LGN of the 
thalamus. From the LGN, signals are projected to the primary visual cortex (V1). At the cortical level, the 
dorsal visual pathway ends in the parietal cortex, whereas the ventral pathway ends in the temporal 
cortex. Note that between dorsal and ventral pathways, there are, at least, three hundred known 
connections (Adapted from Shabana et al., 2003). 
 
 
In summary, M cell information is processed through the “where” (dorsal) 
pathway (important for motion perception and spatial location) to the posterior parietal 
cortex, while information from P cells is mostly processed through the “what” (ventral) 
pathway (important for object recognition, and their neurons respond to properties, such 
as shape, colors and patterns) to the inferotemporal cortex (Goodale and Milner, 1992; 
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Ungerleider and Haxby, 1994; Callaway, 2005; Yoonessi and Yoonessi, 2011). The 
dorsal and ventral pathways are grossly parallel, however there are a complex pattern of 
connections between them (Merigan and Maunsell, 1993). 
 
 
 
1.4. AGING OF THE VISUAL PATHWAY 
 
Gradual decline of visual function is a feature of normal aging. This partly 
results from the combination of optical factors, retinal neural factors such as 
photoreceptor and ganglion cell degeneration and cortical factors (Lam, 2005; Owsley, 
2011). In particular at photopic light levels, spatial CS deficits may also be affected by 
optical characteristics (Owsley, 2011). Aging of the lens is particularly relevant in 
which concerns color vision: lens yellowing might indeed affect the interpretation of 
changes in blue-yellow discrimination tests (Castelo-Branco et al., 2004; Silva et al., 
2005). 
Many visual functions are expected to be impaired in people in the last aging 
decades, which is a rising problem due to changes in demographic structure of western 
populations. Since, the process in healthy and pathological aging is distinct (Graewe et 
al., 2013), it is important perform a hierarchical analysis of low- and high-level visual 
function within multiple visual channels in healthy aging (from early adulthood up to 
old age cohorts), to better understand visual function in pathological aging. 
The influence of normal aging in early, intermediate and high-level visual 
processing is still poorly understood. By other words, a hierarchical approach of visual 
function analysis has not been used before to access aging across the life span. Here we 
attempted to address this issue using a hierarchical approach from the point of view of 
visual processing and stimulus construction. In this way we used chromatic and 
achromatic CS tasks with simple gratings and patches, motion discrimination tasks with 
simple random dots kinetograms (RDK), and high-level object integration tasks using 
the same type of dots. The rationale of this study tackles the principles of the 
organization of the visual system: in the early part of the visual system, information is 
transmitted from the retina to the visual cortex through three parallel and 
physiologically distinct pathways - Parvo, Magno and Koniocellular.  
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We have addressed this important issue in a large cohort of 653 subjects divided 
into five distinct age groups, [20;30[, [30;40[, [40;50[, [50;60[ and [60;[. We applied a 
broad range of psychophysical tests, testing distinct levels of the visual hierarchy, from 
local processing to global integration, using simple gratings [spatial CS using high 
temporal/ low spatial frequency (FDT) or intermediate spatial frequency (ISF) static 
gratings], color CS using Landolt patches (CCT), moving dot stimuli (Local Speed 
Discrimination) and dot patterns defining 3D objects (3D Structure from Motion, 3D 
SFM). 3D tasks (requiring the detection of complex SFM targets) involve high-level 
dorsal stream function and dorso-ventral integration for object recognition (Lemos et 
al., 2012; Graewe et al., 2013). On the other hand, local speed signals are mainly 
processed in early human visual cortex, in particular V1 and V2 (Castelo-Branco et al., 
2002). Finally, chromatic and achromatic CS tests require the integrity of low-level 
retinal or retinocortical visual pathways (Castelo-Branco et al., 2004; Maia-Lopes et al., 
2008; Reis et al., 2011). 
Aging data were fitted with linear or quadratic regression models, using the 
adjusted coefficient of determination (R
2
a) to quantify the effect of aging. A significant 
effect of age was found on all visual channels tested, except for the chromatic channel. 
In our study, red-green and blue-yellow CS testing showed only significant age effects 
in the latter. This seems to be consistent with the relatively stable anatomical cone 
distribution during aging (Curcio et al., 1993) and also with evidence that optical factors 
(yellowing of the crystalline lens) contribute for the gradual decline of color vision 
function with aging, only for stimuli modulated along the tritan axis (Pokorny et al., 
1987). 
The high temporal/ low spatial frequency CS channel showed a mean sensitivity 
loss of 0.75dB per decade (R
2
a=0.17, p<0.001) (see Figure 1.5 for representative 
examples of age-related CS decline obtained with FDT perimetry for each age group), 
while the lower intermediate spatial frequency channel showed a more pronounced 
decrease, around 2.35dB per decade (R
2
a=0.55, p<0.001) (see Figure 1.6 for 
representative examples obtained with ISF perimetry). Concerning low-level motion 
perception, speed discrimination decreased 2.71º/s (R
2
a=0.18, p<0.001) and 3.15º/s per 
decade (R
2
a=0.13, p<0.001) only for short presentations for horizontal and oblique 
meridians, respectively.  
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Figure 1.5. Illustration of gradual decline in achromatic CS over age groups observed with FDT 
perimetry using representative cases for each age group. Greyscale bar depicts contrast sensitivity in 
decibels. Darker regions correspond to worse CS. 
 
 
 
 
Figure 1.6. Illustration of progressive sensitivity loss in achromatic CS over age groups assessed by ISF 
perimetry, using representative cases for each age group. Greyscale bar depicts contrast sensitivity in 
decibels. Darker regions correspond to worse CS. 
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The 3D SFM task showed the strongest (quadratic) decrease of motion 
coherence perception with age, especially when the task was temporally constrained 
(R
2
a=0.54, p<0.001) (Figure 1.7).  
 
 
 
Figure 1.7. Visual dorsal/ventral streams performance during normal aging. High-level functions showed 
a fast deterioration with an accelerating pattern. Error bars depict standard error of the mean (SEM). The 
dependent measure is % of coherence (percentage of signal dots that are necessary for the subject to 
report the presence of a sphere) (*p<0.001). UR, until response; FI, Fixed Presentation Interval. 
 
 
In summary, the mainly affected level of processing that was tested was high-
level visual dorsal-ventral integration using the 3D SFM task. The stimulus used in 
SFM induces the perception of a 3D rotating sphere, in other words, one perceives a 
form or structure based on motion information, so an interaction between motion 
processing areas and brain areas involved in form processing is required (van der 
Boomen et al., 2012). 
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These findings show that visual channels are influenced by aging into different 
extents. The hierarchical age-related decline of visual functions is further substantiated 
by the fact that high-level mechanisms showed a quadratic profile of loss, unlike low-
level mechanisms which in general showed a linear pattern of decay. Only the low-level 
achromatic intermediate frequency CS channel showed comparatively high loss, but 
with a still linear pattern. 
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CHAPTER 2 
 
CLINICAL MODELS OF GANGLION CELL DYSFUNCTION 
 
 
2.1  OPTIC NEUROPATHIES - OVERVIEW 
 
Optic neuropathies (ON) comprise a group of disorders that share the hallmark 
of optic nerve dysfunction. In fact, ganglion cell axonal damage is clinically manifested 
by pathological changes in optic nerve appearance associated with visual acuity loss, 
visual field defects, decreased brightness sensation and color vision impairment 
(Newman, 1996).  
How RGC degeneration (with associated visual loss) occurs is important to 
understand the etiology of the optic neuropathy. In other words, rapid 
pathophysiological processes are characteristic of optic neuritis, ischemic optic 
neuropathy, inflammatory (non-demyelinating) and traumatic optic neuropathy. On the 
other hand, a gradual process is typical of toxic/nutritional optic neuropathy, 
compressive and hereditary optic neuropathies (Behbehani, 2007). Glaucomatous optic 
neuropathy (open-angle glaucoma) is distinguished from other optic neuropathies by 
slow progressive degeneration of RGC and their axons over months to years (Weinreb 
and Khaw, 2004; Quigley, 2011). 
In the inherited forms, the classification of the hereditary ON is based on the 
study of typical clinical features (eventually symmetric and bilateral visual loss with 
concomitant central/cecocentral scotomas due to papillomacular nerve fiber bundle 
damage) and classic patterns of familial transmission. However, genetic analysis is 
important, allowing to diagnose some of these neuropathies even in the absence of 
family history (family members may be subclinically affected) or in the presence of 
unusual clinical presentations (Votruba et al., 2003; Newman and Biousse, 2004; 
Newman, 2005).  
Therefore, this chapter will address one of the most frequent mitochondrial 
hereditary optic neuropathies (Carelli et al., 2009; Yu-Wai-Man et al., 2009), namely 
LHON and also address the most commonly acquired optic neuropathy found in clinical 
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practice, glaucomatous optic neuropathy (O’Neil et al., 2011). These two entities can 
exhibit similar topographical changes at the optic nerve head, particularly in late-stage 
disease, making difficult to differentiate between LHON and open-angle glaucoma only 
based on optic disc assessment (O’Neil et al., 2011). Some clinical features overlap in 
these two optic neuropathies, but there are retinal differences as first manifestations, 
namely on the type of the RGC involved in each disease model: in LHON, the smallest 
RGC are first and preferentially affected (in particular the central thin axons – 
papillomacular bundle) (Sadun et al., 2000; Carelli et al., 2004), while in glaucoma, the 
peripheral large RGC axons are the firstly affected. Interestingly, some histological 
evidence has suggested that damage to larger RGC axons firstly occurs in the natural 
course of glaucoma (Quigley et al., 1987; Quigley et al., 1988). However, ‘larger RGC 
axons’ does not necessarily mean ‘magnocellular axons’. In fact, larger diameter optic 
nerve fibers are not exclusively magnocellular fibers. The size of the fibers is dependent 
on retinal eccentricity as well as ganglion cell type, so some eccentric parvocellular 
RGC axons may be larger than more central magnocellular RGC axons (Perry et al., 
1984; Shabana et al., 2003). 
 
 
 
2.2 LEBER HEREDITARY OPTIC NEUROPATHY 
 
Leber hereditary optic neuropathy (LHON) is a maternally inherited disease, 
which occurs due to mutations in mitochondrial DNA (mtDNA) (Harding et al., 1995; 
Yu-Wai-Man et al., 2009). 
 
 
2.2.1 GENETICS 
 
This hereditary optic neuropathy is transmitted by non-Mendelian 
(mitochondrial) inheritance and, since mitochondria are maternally inherited, there is no 
male to male transmission in a LHON pedigree (Votruba, 2004). 
Over 90% of LHON pedigrees are known to harbor one of these three mtDNA 
point mutations (so-called “primary” LHON mutations): 3460G>A (13% of the cases), 
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11778G>A (69%) and 14484T>C (14%). All mutations involve genes encoding 
complex I subunits of the mitochondrial respiratory chain and are pathogenic in the 
large majority of patients (Mackey et al., 1996; Man et al., 2002; Carelli et al., 2004). 
Molecular genetic testing on a blood DNA sample is the diagnostic gold standard and 
identifies the primary mtDNA mutation of the patient. In most LHON pedigrees, the 
primary mutation is homoplasmic (100% of the mtDNA molecules is mutant), but 10-
15% of LHON carriers are thought to be heteroplasmic (if the mutational load is <60%, 
the risk of blindness is minimal) (Chinnery et al., 2001).  
 
 
2.2.2     CLINICAL FEATURES 
 
LHON is the most common of the primary mtDNA diseases (Chinnery et al., 
2000). The onset of visual loss typically occurs between the ages of 15 and 35 years 
(Newman et al., 1991; Nikoskelainen et al., 1996) and visual failure in 95% of carriers 
will occur before the age of 50 years (Newman, 2005). However, visual deterioration 
can be manifested anytime during the first to the seventh decade of life and it is 
generally accepted that neither gender nor mutational status significantly influences the 
timing and severity of the initial visual loss (Yu-Wai-Man et al., 2009).  
In a pre-symptomatic phase, some asymptomatic carriers present telangiectatic 
vessels around the optic discs and swelling of the peripapillary RNFL (pseudoedema) 
(Newman, 2005; Yu-Wai-Man et al., 2009). Using optical coherence tomography 
(OCT) imaging, a swelling of the papillomacular bundle in temporal and inferior 
quadrants can be observed (Savini et al., 2005). On psychophysical testing, some 
individuals exhibited subtle impairment of optic nerve function, namely loss of color 
vision affecting mostly the red-green system and also reduced CS (Quiros et al., 2006; 
Sadun et al., 2006; Ventura et al., 2007). In fact, there is an early involvement of the 
axons that form the papillomacular bundle (small caliber fibers), which is the 
anatomical substrate for central and color vision (Sadun et al., 2000; Carelli et al., 
2004).  
LHON carriers remain asymptomatic until they experience rapid and painless 
loss of central vision in one eye (acute phase - first six months). In the majority of cases, 
visual dysfunction is bilateral, the fellow eye becoming affected simultaneously (25%) 
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or sequentially (75%), with a median inter-eye delay of 6-8 weeks (Harding et al., 
1995). Visual acuity reaches its lowest value 4-6 weeks after disease onset and it is 
severely reduced to 6/60 or less (Yu-Wai-Man et al., 2009). Patients present 
characteristic large central or centro-cecal absolute scotomas on visual field and also 
impairment of color vision perception (Newman et al., 1991; Nikoskelainen et al., 
1996). The characteristic signs at fundus examination include vascular tortuosity of the 
central retinal vessels, circumpapillary telangiectatic microangiopathy, swelling of the 
RNFL around the disc (pseudoedema) (OCT shows swelling of RNFL in the 
superior/inferior quadrant, but also loss of the papillomacular bundle temporal fibers; 
Barboni et al., 2005) and absence of leakage from the disc or papillary region on 
fluorescein angiography (in contrast to the true disc edema) (Smith et al., 1973; Carelli 
et al., 2004). However, the optic disc may look entirely normal in the acute phase in 
about 20% of LHON cases. 
The optic disc appears hyperemic initially, though the axonal loss in the 
papillomacular bundle leads to severe temporal atrophy of the optic disc (Carelli et al., 
2009). The RNFL gradually degenerates (OCT shows severe loss of fibers in all 
quadrants in chronic phase, the nasal being the most spared; Barboni et al., 2005) and, 
after 6 months, optic disc turns completely atrophic (Yu-Wai-Man et al., 2009).  
As expected, some magnetic resonance imaging (MRI) studies have 
demonstrated signs of atrophy and increased T2-weighted signal in optic nerves of 
LHON patients (Kermode et al., 1989; Morrisey et al., 1995). MR spectroscopy studies 
have found a non selective and isolated involvement of the optic nerve, reporting an 
abnormal mitochondrial energy metabolism in the occipital lobe from these patients 
(Cortelli et al., 1991; Barbiroli et al., 1995; Lodi et al., 2002). Using MRI and voxel-
based morphometry (VMB), Barcella et al. (2010) have described a significant reduced 
grey matter volume in bilateral primary visual cortex, as well as reduced white matter 
volume in optic chiasm, optic tract and optic radiations, in LHON patients.    
Optic atrophy with permanent severe loss of central vision but with relative 
preservation of papillary light responses is the usual endpoint of the disease (Carelli et 
al., 2004). However, in some patients, even years after disease onset, spontaneous 
recovery is occasionally observed (Newman et al., 1991; Stone et al., 1992; 
Nikoskelainen et al., 1996; Pezzi et al., 1998). The recovery is not only restricted to 
visual acuity, including the development of small islands of normal field within the 
central scotoma or a reversal of color vision impairment (Stone et al., 1992). An early 
Pathophysiological mechanisms and novel biomarkers in acquired and genetic diseases of the RGC 
 
- 19 - 
 
age of disease onset (<20 years) is not necessarily an unfavorable prognostic factor and 
the rate of visual recovery seems to be closely related to the type of pathogenic mutation 
(changes of visual recovery are highest in the presence of 14484T>C mutation, lowest 
in 11778G>A mutation and intermediate in 3460G>A mutation) (Oostra et al., 1994; 
Carelli et al., 2004; Yu-Wai-Man et al., 2009). However, the majority of patients show 
no functional improvement. Respiratory dysfunction may lead to axoplasmic stasis and 
swelling, with evidence of demyelination, and if mitochondrial apoptotic pathway is 
activated, RGC are permanently lost (Votruba, 2004).   
  
 
2.2.3     PATHOPHYSIOLOGY 
 
Mitochondria play an essential role in the life and death of cells, including 
neurons. All mitochondria are produced in the RGC somata and must be transported to 
the axonal terminal by axoplasmic transport, which is very energy-demanding, and 
distributed along strategic locations in the optic nerve (Sadun, 1998; Carelli et al., 
2004). Among other factors, efficient transportation of mitochondria depends on their 
own energy production and adequate myelination of the axons. 
 The human optic nerve is comprised of approximately 1.2 million unmyelinated 
RGC axons. These axons, originate at the RGC cell bodies, travel within the nerve fiber 
layer toward the optic nerve head, and then turn sharply at the disc through the lamina 
cribrosa to form the optic nerve, gaining their myelin sheath in the process (Yu Wai 
Man et al., 2005; Carelli et al., 2009). Asymmetric patterns of myelination may have 
functional implications on energy dependence and distribution of mitochondrial 
populations in the different sections of the optic nerve. Once RCG axons achieve 
myelination, their energy dependence decreases drastically (Carelli et al., 2009). 
Accordingly, histological and histochemical techniques have shown a non-
homogeneous distribution of mitochondria along the optic nerve axons (Carelli et al., 
2002). As expected, the mitochondrial density is higher in the prelaminar region but 
drastically decreases in the postlaminar section (Yu Wai Man et al., 2005). Thus, the 
prelaminar portion of optic nerve may be particularly vulnerable to mitochondrial 
dysfunction (Newman and Biousse, 2004).  
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Histopathological studies in LHON patients with long-standing visual loss show 
axonal degeneration in the optic nerve and loss of myelin, and evidence that the small/ 
thinly fibers, mostly belonging to the papillomacular bundle (centrally in the optic 
nerve) are particularly vulnerable (Sadun et al., 2000; Votruba, 2004).   
Small diameter fibers present the lowest volume to surface area ratio, having the 
least margin for error in the setting of energy depletion (the energy expenditure of an 
axon is related to its surface area, while the content of mitochondria is constrained by 
the cell’s volume) (Sadun, 1998; Sadun et al., 2000). They also have a thinner myelin 
sheath and a rapid rate of firing. Thus, these fibers have the most disadvantageous 
condition in terms of energy dependence for maintaining efficient axoplasmic transport 
(Sadun, 1998). Considering the energy depletion (impairment of ATP production by the 
mitochondria), possibly induced by the LHON pathogenic mtDNA mutations (Sadun et 
al., 2000), the most vulnerable component of the optic nerve would be the 
papillomacular bundle, particularly at the prelaminar (unmyelinated) portion of the optic 
nerve head (Carelli et al., 2002).  
Energy depletion and impairment in axoplasmic transport with compensatory 
increase of mitochondrial biogenesis may initially result in swelling of the most 
vulnerable smaller axons (Barboni et al., 2010) and possibly lead to signaling that 
activates the apoptotic cascade and the subsequent preferential death of RGC with 
smallest-caliber axons (Sadun et al., 2000) 
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2.3 GLAUCOMATOUS OPTIC NEUROPATHY 
 
Glaucoma is an optic neuropathy that is characterized by a slow progressive 
degeneration of RGC and their axons, resulting in changes in the optic disc and retinal 
nerve fiber layer (RNFL) with a concomitant pattern of progressive visual loss and 
visual field defect (Weinreb and Khaw, 2004; Quigley, 2011). In fact, vision loss caused 
by glaucoma is irreversible, making this disease the second leading cause of blindness 
in the world (Kingman, 2004; Resnikoff et al., 2004). It was estimated that, in 2010, 
60.5 million people had glaucoma and this number is expected to increase up to 79.6 
million in 2020 (Quigley and Broman, 2006). However, the scope of the problem is 
probably larger, since several epidemiological studies have shown that at least half of 
glaucoma patients are undiagnosed (Burr et al., 2007). 
The glaucoma is classified by the appearance of the iridocorneal angle. There are 
open-angle, closed-angle and developmental categories, which are further divided into 
primary and secondary forms (Kwon et al., 2009). Primary open-angle glaucoma 
(POAG) is the most common type of glaucoma. In POAG the iridocorneal angle is 
unobstructed and with normal appearance but aqueous humour outflow is diminished. 
Although elevated intraocular pressure (IOP) is not part of the clinical definition 
because POAG can occur when it is normal (normal-tension glaucoma), elevated IOP is 
a prominent risk factor for developing optic nerve glaucomatous damage (Bahrami, 
2006; Kwon et al., 2009). Besides an elevated IOP, a thin central corneal thickness 
could be associated with a major risk for the development and progression of the 
disease (Chauhan et al., 2005; European Glaucoma Prevention Study Group, 2007). 
There is also a good evidence that black race (high prevalence of POAG in Africans as 
compared with European or Asian people), older age (the mean age of onset is typically 
after the age of 40 years and the frequency of this disease rises with age), family history 
of POAG (first-degree relatives have up to ten times increased risk for developing the 
disease compared with the general population) and a high myopia are risk factors for 
POAG (Tielsch et al., 1991; Wolfs et al., 1998; Leske et al., 2001; Weinreb and Khaw, 
2004; Falkenber and Bex, 2007).  
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2.3.1 GENETICS 
 
Details about the inheritance of the POAG remain unclear. No single Mendelian 
mode of inheritance can adequately describe this disease.  
Myocilin is a secreted, glycosylated protein of 504 amino acids with two major 
domains: a coiled coil domain near the amino terminus, and an olfactomedin-like 
domain near the carboxy terminus (Liu and Vollrath, 2004). This protein is produced in 
many tissues, including the ciliary body and trabecular meshwork - the two ocular 
tissues that regulate IOP (Kwon et al., 2009). In fact, myocilin is expressed in many 
ocular and non-ocular tissues and it is found in both intracellular and extracellular 
spaces. However, the normal/physiologic function of this protein is unknown and how 
changes in myocilin expression or presence of myocilin mutations may lead to 
glaucoma have yet to be identified (Fingert et al., 2002; Resch and Fautsch, 2009).  
The MYOC gene (at GLC1A locus), which encodes the protein myocilin, was 
identified as the first gene linked to early and late-onset POAG (Stone et al., 1997; 
Alward et al., 1998; Fingert et al., 1999). The vast majority (more than 90%) of 
glaucoma associated MYOC mutations was found within the large segment of myocilin 
protein (exon 3) that is homologous to the olfactomedin proteins (Resch and Fautsch, 
2009; Kwon et al., 2009). 
Some MYOC mutations have been detected in a sufficient number of patients to 
allow identification of some mutation-specific glaucoma phenotypes, including age at 
onset and maximum IOP: individuals with the T377M mutation are generally diagnosed 
in their 4
th
 life decade, later than the P370L mutation (1
st
 and 2
nd
) and Y437H (2
nd
 
decade; 44 mmHg mean maximal IOP), but earlier than the most common disease-
associated mutation in Caucasians, Q368X (average onset in 5
th
 and 6
th
 decades; 30 
mmHg mean maximal IOP) (Alward et al., 1998; Fingert et al., 1999; Shimizu et al., 
2000; Fingert et al., 2002). In fact, mutations associated with early-onset POAG lead to 
the greatest elevations in IOP (about 40 mmHg), whereas mutations associated with 
late-onset typically cause maximum pressures of 25 to 40 mmHg (Kwon et al., 2009). 
Some studies indicate that myocilin is possibly secreted from ocular tissues that 
may include the trabecular meshwork or ciliary body (Jacobson et al., 2001). Patients 
with glaucoma-associated MYOC mutations showed dramatic decrease in secretion of 
myocilin in trabecular meshwork cells and reduced quantity of myocilin into the 
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aqueous humor, suggesting that failure to secrete myocilin is a central feature in the 
pathogenesis of myocilin-associated glaucoma (Jacobson et al., 2001). There is also 
evidence that mutant myocilin may be retained within the intracellular space by means 
of an anormal association with other proteins (Shepard et al., 2007). Mutant myocilin 
accumulated in the intracellular space may be toxic to trabecular-meshwork cells, 
initiating a cascade of events that begins with loss of function in these cells (Kwon et 
al., 2009). The retention of mutant myocilin potentially cause a stiffer, less-pliable 
trabecular meshwork, possibly increasing resistance to aqueous outflow and elevating 
IOP (Wentz-Hunter et al., 2004; Resch and Fautsch, 2009). Regardless of the retention 
mechanism, decreased secretion and increased accumulation of intracellular myocilin 
appear to be the first steps in the pathogenesis of myocilin-associated glaucoma (Kwon 
et al., 2009). 
Several large studies suggested that myocilin mutations have been found in 2-
4% of cases of adult-onset POAG and more than 10% in juvenile-onset cases (Stone et 
al., 1997; Fingert et al., 1999). Perhaps due to the low prevalence of myocilin-
associated glaucoma in the general population, screening tests of whole populations for 
myocilin defects are not especially useful.    
 
 
2.3.2 CLINICAL FEATURES 
 
POAG is a chronic asymptomatic disease, generally bilateral, but often 
asymmetrical, that is characterized by progressive dysfunction or death of the RGC 
axons as shown by changes in the optic disc, thinning of retinal nerve fiber layer and 
visual field loss (Weinreb and Khaw, 2004; Anderson, 2006). Many glaucomatous 
patients present an elevated IOP, although it is extremely important to evaluate the 
central corneal thickness, since this measure can mask the real IOP (European 
Glaucoma Society, 2008). 
It is known that, in normal subjects, the convergence of the RGC axons forms a 
central physiological depression in the optic disc (so called “cup”) and the neuroretinal 
rim of the optic nerve head surrounds this cup. In the case of glaucomatous neuropathy, 
as more RGC and their axons are affected and lost, more the width of the neuroretinal 
rim decreases, as well as the thickness of the RNFL surrounding the disc. 
Pathophysiological mechanisms and novel biomarkers in acquired and genetic diseases of the RGC 
 
- 24 - 
 
Concomitantly, there is a deepening and widening of the cup (cup-to-disc ratio 
progressively increases) - see Figure 2.1. The optic disc excavation occurs not only due 
to the loss of RGC axons, but also due to deformation of connective tissues supporting 
the optic disc (Weinreb and Khaw, 2004). In summary, evidence of glaucomatous optic 
disc damage is defined by the presence of excavation, neuroretinal rim thinning or 
notching and/or retinal nerve fiber defects (Johnson et al., 2003). 
 
 
 
Figure 2.1. Longitudinal cross-section of normal (A) and glaucomatous optic nerve head (B). The lamina 
cribrosa undergoes deformation (blue arrows), leading to a significant loss of RGC and their axons with 
concomitant thinning of RNFL, decrease of the neuroretinal rim and an increased cupping of the optic 
nerve disc (black arrows) (Adapted from Kwon et al., 2009). 
 
Thus, examination of the optic disc is an important and valuable method for 
diagnosing early glaucoma, because changes in the optic nerve appearance often occur 
before overt visual field loss (Sommer et al., 1991; Artes and Chauhan, 2005; Sharma et 
al., 2008). Some objective and quantitative methods have emerged to assess the 
structural changes of the optic disc and RNFL, namely scanning laser polarimetry (to 
assess the RNFL thickness), confocal scanning laser ophthalmoscopy (to measure the 
topography of the optic disc and to quantify the area of the optic disc cup and the 
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neuroretinal rim) and OCT (to measure RNFL thickness and to visualize the optic disc 
topography) (Sharma et al., 2008).  
The functional loss is traditionally assessed by quantifying light sensitivity at 
specific visual field locations within the central 30 degrees, using a white-on-white 
standard automated perimetry (SAP) - golden standard (Anderson, 2006; Sharma et al., 
2008). The characteristic visual field defects include a nasal step scotoma that respects 
the horizontal raphe, inferior or superior arcuate scotoma, paracentral scotoma or 
generalized depression (Weinreb and Khaw, 2004) (Figure 2.2). Since peripheral vision 
is most susceptible to glaucomatous damage, loss of central visual acuity typically 
occurs only in the end stage of disease. 
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Figure 2.2. Visual field results across different stages of glaucoma (A, B, C): Damage usually starts in 
the nasal field (upper or lower half quadrant) (A); Mid-stage disease shows pronounced loss in the initial 
hemifield, which can be extended to the opposite hemifield (B); At an end-stage disease, before the entire 
visual field becomes affected, only an island of vision remains (C). Representative example of a normal 
visual field (D). 
 
It is known that SAP does not test selectively a particular RGC type, being 
insensitive to early RGC dysfunction. Under the current conditions of SAP, the white 
stimulus is detected by all sub-systems in the retina and, if a few cells of a specific 
subtype become dysfunctional, the stimulus can still be detected by different types of 
Pathophysiological mechanisms and novel biomarkers in acquired and genetic diseases of the RGC 
 
- 27 - 
 
functional cell populations, which ‘fill the gap’ (Anderson, 2006). In fact, a significant 
fraction of RGC may be permanently lost when a visual defect becomes apparent in 
visual field testing (Quigley et al., 1989; Harwerth et al., 1999; Kerrigan-Baumrind et 
al., 2000). In this sense, selective functional visual tests, which aim to isolate specific 
RGC populations, losing the redundancy afforded by the other cell types, might 
potentially be better suited to identify glaucomatous defects earlier than standard visual 
field testing (Johnson et al., 1993; Maddess et al., 1999; Castelo-Branco et al., 2004; 
Spry et al., 2005; Bagga et al., 2006). For instance, frequency doubling technology 
perimetry (FDT), which uses a vertical sinusoidal grating of low spatial frequency that 
undergoes counterphase flickering at a high temporal frequency, producing an illusory 
double spatial frequency (Turpin et al., 2002a; Silva et al., 2008), predominately 
stimulates the magnocellular RGC pathway (My-subtype) (Sample et al., 2000) and can 
reveal early losses before they can be found using conventional clinical test procedures 
(Johnson and Samuels, 1997; Brusini and Brusatto, 1998; Landers et al., 2000; Cello et 
al., 2000; Cellini et al., 2012). On the other hand, short-wavelength automated 
perimetry (SWAP), which uses a blue stimulus over a yellow background and 
selectively tests the koniocellular ganglion cell pathway (Sample et al., 2000), 
consistently shows visual field defects even at a pre-SAP loss stage, suggesting that 
magnocellular axons are not the only ones affected in the early disease stages and that 
the pathological process does probably affect several subsets of RGC (Johnson et al., 
1993; Casson et al., 1993). 
Color vision impairment is also observed in glaucoma patients, not only in the 
later stages of the disease, but also in the ocular hypertension stage (Castelo-Branco et 
al., 2004). It is widely believed that glaucoma is predominantly associated with tritan-
like defects (Johnson et al., 1993; Heron et al., 1994; Felius et al., 1995; Gray et al., 
1995; Sample et al., 1997). Although most studies imply a predominant involvement of 
the koniocellular pathway, an important parvocellular dysfunction has also been 
reported (Greenstein et al., 1996; Alvarez et al., 1997; Castelo-Branco et al., 2004).  
Interestingly, there is evidence (neuroimaging studies) that glaucomatous 
damage extends from RGC to neurons in all structures along the visual pathway, 
including the optic nerve, optic chiasm, lateral geniculate nucleus and primary visual 
cortex (Yücel et al., 2003; Duncan et al., 2007a; Duncan et al., 2007b; Qing et al., 2010; 
Hernowo et al., 2011; Dai et al., 2013). 
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Since the disease progression can frequently be arrested or slowed with medical 
and surgical treatment and the visual impairment caused by glaucoma is irreversible, 
early detection is critical (Sharma et al., 2008). Early diagnosis of POAG typically 
relies on examination of structural damage of the optic nerve combined with 
measurements of visual function. New imaging and psychophysical tests can certainly 
improve both early detection and monitoring of disease progression.  
 
 
2.3.3 PATHOPHYSIOLOGY 
 
Retinal ganglion cell death or dysfunction is the pathological hallmark of 
glaucoma, albeit the pathophysiology of the progressive impairment of RGC is not fully 
understood (Weinreb and Khaw, 2004; Anderson, 2006). Most of the theories 
concerning the pathogenesis of glaucoma can be grouped in two broad categories: 
mechanical (IOP-related) and vasogenic (Fechtner and Weinreb, 1994). 
The level of IOP is unquestionably related to the death of RGC and optic nerve 
fibers in some, but not in all, patients with POAG. Although no obstruction can be 
observed with clinical examination, resistance to aqueous outflow through the 
trabecular meshwork is increased in patients with this type of glaucoma. 
Clinical observations have indicated that the lamina cribrosa is the initial site of 
glaucomatous damage (Quigley, 1999). Lamina cribrosa consists of about ten lamellar 
sheets with pores which align to form about 400 to 500 channels through which pass the 
axons of the RGC grouped into optic nerve fiber bundles. The lamina cribrosa supports 
and separates unmyelinated prelaminar RGC axons from myelinated postlaminar RGC 
axons (Kwon et al., 2009). Within the collagenous beams of the lamina cribrosa are 
blood vessels and extracellular matrix components which contribute to the nourishment 
of the axons together with axonal transport (Fechtner and Weinreb, 1994).  
Some studies in vitro have shown that high pressure can distort the lamina 
cribrosa (Levy et al., 1981; Zeimer and Ogura, 1989). In fact, when IOP increases above 
physiological levels, the pressure gradient across the lamina cribrosa and the RGC 
axons undergo deformation and mechanical stress (Bellezza et al., 2003). A structural 
change in the lamina cribrosa related with high pressure may result in changes in 
orientation or collapse of the laminar channels which could distort the alignment of the 
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axonal channels producing direct mechanical impingements on nerve fibers (Fechtner 
and Weinreb, 1994). These may cause damage of RGC axons not only by mechanical 
factors, but also by compromising blood flow and delivery of nutrients to the axons.  
With this line of evidence, some experimental models postulate a blockade of 
RGC axonal transport due to IOP-induced compression of optic nerve axons at the 
lamina cribrosa, which can reduce retrograde axoplasmic flow, causing stress of the 
cells and their death by deprivation of neurotrophic factors (Quigley et al., 2000). On 
the other hand, if blood perfusion at the optic nerve head is persistently reduced 
(Mozaffarieh et al., 2008), tissue hypoxia can induce the formation and accumulation of 
reactive oxygen species in the retina, causing cellular stress and malfunction (Ko et al., 
2005).  
Interestingly, regional differences in the lamina cribrosa may also account for 
some of the characteristic patterns of damage seen in glaucoma (Figure 2.3). The lamina 
cribrosa septae is more closely packed and thicker along the horizontal meridian of the 
nerve, including areas corresponding to retinal nerve fibers subserving the central and 
temporal portion of the visual field, which are relatively spared (Quigley and Addicks, 
1981). In these areas, the thick septae may be more resistant to mechanical deformation, 
sparing the nerve fibers from injury until a late stage in the course of the disease 
(Fechtner and Weinreb, 1994). In addition, the largest pores of the lamina cribrosa are 
typically arranged in an hourglass configuration at the superior and inferior poles of the 
optic nerve head. These areas are composed by a high proportion of large diameters 
fibers subserving the arcuate regions, suggesting an increased vulnerability of these 
fibers to pressure-related damage (Fechtner and Weinreb, 1994). 
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Figure 2.3. Human lamina cribrosa demonstrating pores through which pass RGC axons. Note schematic 
representation of typical hourglass arrangement of pores (blue lines) with the largest pores found in the 
superior and inferior poles (Adapted from Quigley, 2011). 
 
Although elevated IOP is considered to be a prominent risk factor for POAG, 
this cannot explain the fact that some individuals with ocular hypertension do never 
develop glaucomatous damage, while others with normal IOP do. There are normal-
tension glaucoma patients in whom optic nerve and visual field changes occur similarly 
to alterations in POAG patients. Thus, other factors must play an important role in 
glaucoma pathogenesis. 
There is considerable evidence supporting the concept that changes within the 
microcirculation may be relevant to the POAG development. It was suggested by Ernest 
(1975) that a faulty autoregulation of ocular microcirculation may contribute to the 
pathogenesis of POAG (Ernest, 1975). The retina and optic nerve are dependent on their 
blood supply for satisfying the high metabolic needs, and local ischaemia-hypoxia, 
maybe due to dysfunction of blood-flow autoregulation, has been implicated as one of 
the possible factors that could cause POAG (Weinreb and Khaw, 2004). 
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CHAPTER 3 
 
METHODOLOGICAL OVERVIEW 
 
 
3.1 FUNCTIONAL ASSESSMENT 
3.1.1 PSYCHOPHYSICS 
3.1.1.1 CHROMATIC CONTRAST SENSITIVITY 
 
We have probed chromatic contrast sensitivities using a computer-controlled 
psychophysical method, a slightly modified version of Cambridge Color Test (CCT; 
Cambridge Research Systems Lda., CRS, Rochester, UK) (Silva et al., 2005; Mateus et 
al., 2013). This technique uses three parallel, randomly interleaved staircases, 
corresponding to simultaneous assessment of the three cone confusion axes (protan/red, 
deutan/green and tritan/blue) modulated in the CIE 1976 u’v’ color space (Trivector 
version of the test). Each staircase was composed by 11 reversals and the mean of the 
last 7 reversals was taken as the threshold estimate. Subjects looked monocularly (the 
first eye tested was chosen in a random manner) at a screen (21-inch monitor; viewing 
distance - 180cm) with a static pattern of circles of various sizes and luminances with 
superimposed chromatic contrast defining a Landolt-like C-shaped ring (gap size: 1.6º; 
outer diameter: 7.6º; inner diameter: 3.81º), which forces the subject to use specific 
color cues (see Figure 3.1). These patches were randomly assigned six different 
luminance noise levels (8 to 18cd/m
2
 in steps of two units). Subjects were instructed to 
indicate one out of four possible gap positions (up, down, left or right) of the Landolt C 
stimulus, by pressing one of four buttons of the response box. Psychophysical 
thresholds were expressed in CIE 1976 u’v’ color space units. Note that high chromatic 
thresholds relate to low CS. 
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Figure 3.1. Schematic illustration of the stimuli used in the Cambridge Color Test, representing a 
luminance noise stimulus with superimposed chromatic target (Landolt C shape, colored in red). 
 
 
3.1.1.2 ACHROMATIC CONTRAST SENSITIVITY 
 
Frequency Doubling Technology (FDT) perimeter (Humphrey Matrix perimeter, 
Welch Allyn, Skaneateles, NY; Zeiss – Humphrey, Dublin, CA) determines CS 
measures for detection of sinusoidal gratings with spatial frequency of 0.25cpd 
undergoing counterphase flicker at 25Hz (Turpin et al., 2002b; Silva et al., 2008). We 
performed N-30-F FDT full threshold test, which uses a staircase threshold strategy 
known as a Modified Binary Search (MOBS) with a four-reversals rule for determining 
the threshold level. The range of possible threshold level values for the raw data is 
between 0 dB Maximum Contrast and 56 dB Minimum Contrast. Stimulus duration was 
300 ms and background luminance was 100 cd/m
2
. Stimuli (10º by 10º squares, except 
for a 5º radius central circular target) were presented at 17 locations, plus 2 nasal 
locations, testing 30º nasally and 20º temporally (Figure 3.2).  
Performance reliability was assessed by monitoring fixation loss and computing 
false positive and negative errors (results with false positive and negative errors ≥ 33% 
and fixation loss ≥ 20% were excluded (Caprioli, 1991; Clement et al., 2009)). In this 
study, subjects were instructed to fixate the black square in the centre of the screen and 
report the presence of “striped” targets. All participants performed the test under 
monocular conditions. 
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Figure 3.2. Schematic representation of the 17 visual field locations plus 2 nasal positions tested in FDT 
task. The black square in the middle of the figure represents the fixation square. Sinusoidal gratings were 
used as detection target stimuli. 
 
Statistical analysis was performed considering both global indices, mean 
deviation (MD) and pattern standard deviation (PSD). For analysis purposes, 4 visual 
field quadrants (inferior nasal, IN; inferior temporal, IT; superior nasal, SN; superior 
temporal, ST) and 3 zones were defined: zone 1 corresponds to 5º of visual field, zone 2 
contains locations between 5º and 10º eccentricity and zone 3 contains locations 
between 10º and 20º temporally or 30º nasally. 
 
 
3.1.1.3 STANDARD AUTOMATED PERIMETRY 
 
Octopus Perimeter 
 
The LHON carriers group performed the SAP, using a commercially available 
system Octopus version 311 (Haag-Streit AG, Germany) (Reis et al., 2013). Patients 
were instructed to fixate the central point and report the presence of bright targets, 
which could appear in 76 different locations within 30º of visual field (program 32, 
stimulus size: Goldmann III; stimulus duration: 100 ms). Threshold data was obtained 
with the TOP (tendency oriented perimetry) strategy (Moraled et al., 2000), in which 
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every answer at a particular point is taken into account in the adjustments of the 
neighboring locations. 
The test was performed under monocular conditions, being the first eye tested 
chosen in a random manner. Performance reliability was assessed by computing false 
positive and negative errors (results with false positive and negative errors ≥ 33% were 
excluded). Fixation loss was monitored during the examination, although an electronic 
eye fixation control system. This system interrupts the examination and notifies if 
patient is not fixating or is closing the eye. Global indices as mean sensitivity (MS), 
mean defect (MDf) and loss variance (LV) were analyzed. We also obtained the mean 
sensitivity of two rings (ring 1, central circle with 15º of radius; ring 2, 30º of radius). 
According to device manual, a normal visual field shows a MDf between -2 and +2 dB 
and a LV < 6 dB
2
. 
 
 
Humphrey Perimeter 
 
Automated visual fields were performed on the Humphrey Field Analyzer (HFA 
II, Carl Zeiss Meditec, Dublin, CA) in the case of glaucomatous patients. They were 
instructed to report the presence of bright targets (white stimulus, size Goldmann III), 
which could appear in 76 different locations within 30º of visual field (SITA-Fast 
strategy, 30-2 standard program). 
The test was performed under monocular conditions and the first eye tested was 
chosen in a random manner. Performance reliability was assessed by computing fixation 
loss and false positive/negative errors (results with false positive/ negative errors ≥ 33% 
and/or fixation loss ≥ 20% were excluded (Caprioli, 1991; Clement et al., 2009)). 
Global parameter as mean deviation (MD) was analyzed: MD more than -2 dB or > 5% 
of confidence interval is characteristic of a normal visual field. 
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3.1.1.4 NOVEL PSYCHOPHYSICAL MOTION, ACHROMATIC 
CONTRAST AND CHROMATIC CONTRAST 
DISCRIMINATION TESTS 
 
Set-Up 
 
Our experiments were setup in MATLAB® (MATLAB® 2011a, The 
Mathworks Inc, Natick, MA, USA), using the Psychophysics Toolbox (PTB-3) 
extensions (Brainard, 1997; Pelli, 1997; Kleiner et al., 2007). All stimuli were presented 
on a 24” LCD-IPS monitor (ColorEdge CG243W, Eizo®, Japan) with a native screen 
resolution of 1920x1200 pixels and a refresh rate of 60 Hz. It is important to point out 
that although our monitor has a resolution of 10 bits, we only accessed 8 bits, which 
was adequate for the purposes (detection task) of our experiment (see below). Monitor 
characterization was implemented as described by Brainard et al. (2002), and all 
spectral and luminance measurements were made using a calibrated spectroradiometer 
(PR-650 SpectraScan Colorimeter, Photo Research Inc., Chatsworth, PA, USA).  
In terms of luminance response, we conducted an extensive channel independent 
characterization with 60 points per color channel. We found that this LCD-IPS monitor 
luminance response follows a power-law curve, with a nonlinearity similar to those 
found in CRT monitor models, which can be fitted with high correlation coefficient by 
the following power-type function: l = a * (rgb)^
b + c [where “l” stands for luminance in 
cd/m
2
; rgb represents each channel (red, green, blue) digital number related to channel 
stimulation power - in the graphics this rgb value is normalized to the unit; and finally 
“a”, “b” and “c” are curve fit parameters, “b” is also known as the Gamma power 
value]. This LCD-IPS monitor also presents low angular dependence, good channel 
constancy, and high spatial homogeneity. In order to check for channel spectrum 
constancy, each channel spectrum response was tested in different powers (20%, 40%, 
60%, 80%, 100%). We found good spectrum stability at different stimulation powers, 
from which we can construct a linear model typical to those models for CRT monitors, 
where the monitor emission spectrum for each RGB combination can be obtained with 
negligible error by independent summation of independent color channel spectrum 
weighted by it stimulation power.  Also, we tested this monitor color gamut, and found 
that it is superior to CRT typical models.    
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General Test Features 
 
We developed three novel 2AFC (two-alternative forced choice) psychophysical 
tests that required the comparison and discrimination of a visual feature (motion, 
achromatic contrast and chromatic contrast) between two separated moving single dots 
(a reference dot and a target dot, which were presented in opposite hemifields). 
The use of physically similar stimuli allows for better comparison, the reference 
and target dots only differ in the visual feature being measured. We used two squared 
dots measuring 0.3ºx0.3º for the motion discrimination test and 0.6ºx0.6º for both 
achromatic and chromatic contrast discrimination tests. Fixation on a black central cross 
(size of 1º) was present during all the tests and central fixation was monitored online 
using a camera. The grey background for all tests had a luminance of 25 cd/m
2
. During 
400 ms trials, the reference and target dots were simultaneously presented on randomly 
alternated visual hemifields, moving back and forth along a 2º pseudo-random linear 
trajectory (between 0º and 180º). The experiments took place in a darkened room where 
subjects executed the experiments monocularly (only the dominant eye was tested), 
with refraction corrected for distance and 50 cm away from the display system. Each 
test was repeated four times, corresponding to one of four different 
meridian/eccentricity pairs (the horizontal meridian, 0º, was tested at 7.5º of 
eccentricity; the vertical meridian, 90º, at 10º; the oblique meridians, 45º and 135º, at 
15º) (see Figure 3.3, schematic illustration of the three tasks). 
After each trial, the subject gave a verbal response (the instruction for each test 
is described below) which the experimenter stored by means of a standard keyboard 
(due to the subject’s average age and to avoid motor errors). There was no time limit for 
this response. 
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Figure 3.3. Schematic illustration of motion (Mo), achromatic contrast (C) and S-cone chromatic contrast 
test (S) stimuli, at 0º, 90º and 45º meridians with an eccentricity of 7.5º, 10º and 15º, respectively. The 
tests consist of the discriminative comparison of moving dots, a reference dot (ref) and a target dot (trg), 
which differ on a specific visual attribute being tested (in Mo, a motion/speed difference between dots; in 
C, a luminance difference and in S, a chrominance, S-cone selective, difference). 
 
 
Staircase 
 
 Each visual feature being evaluated was estimated by using a non linear 
logarithmic staircase procedure. In this procedure, the tests ended after 6 reversals and a 
discrimination threshold was calculated using the arithmetic mean of the last 4 
reversals. In each trial, the staircase feeds the display software with the visual feature 
estimation to be visually displayed on the target dot, then the display software computes 
the best match between what the display monitor can really show (based on monitor 
characterization), and the estimated value asked by the staircase. The best match value 
is then feedback to the staircase to substitute the asked value, and the trial is finally 
constructed around this best match value. In the end of each trial the software program 
feeds the staircase with the subject's response, and then calculates the next step based on 
subject's answer, restarting this cycle one more time.  
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Psychophysical tests 
 
Motion discrimination test 
 
In the motion discrimination test, the reference and target dots consisted of two 
white dots moving at different velocities. The reference dot velocity was always 5 deg/s 
(visual degrees per second), while the target dot velocity started at 24 deg/s (physically 
matched in luminance, 30 cd/m
2 
) and was then manipulated by the logarithmic staircase 
procedure (maximum step size of 1 dB and minimum of 0.05 dB). The subject was 
asked “Which dot is moving faster?” and answered either “Left/Right” (for the 
horizontal meridian) or “Up/Down” (for the vertical and oblique meridians). 
 
Achromatic contrast discrimination test 
 
In the achromatic contrast discrimination test (or, more precisely, achromatic 
luminance discrimination), both reference and target dots moved at the same velocity (5 
deg/s), and a grey equal appearance with R=G=B, but their luminance was distinct. The 
reference dot had a fixed luminance of 30 cd/m
2
, while the target dot had a variable 
luminance that started at 70 cd/m
2 
and was then manipulated by the logarithmic 
staircase procedure (maximum step size of 1 dB and minimum of 0.3 dB). For better 
accuracy in calculating luminance stimulus, we made a characterization just in grey 
color (R=G=B), which culminates in the fitted power-law function with the following 
parameters a=72.2384, b=2.2095, c=0.1464, has described before.  
Importantly, concerning the luminance tests, our monitor characterization data 
shows that step sizes are rather small at a global luminance around 30 cd/m
2
, allowing 
for good luminance contrast steps in this range. The continuous working of the 
logarithmic staircase procedure if the subject can effectively spot the luminance 
differences between the two dots, brings the target dot toward this high resolution area, 
where we can find smaller luminance levels, even with an 8-bit channel graphics card. 
The subject was asked “Which dot is brighter?” and answered either “Left/Right” (for 
the horizontal meridian) or “Up/Down” (for the vertical and oblique meridians). 
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Chromatic contrast discrimination test 
 
The chromatic contrast discrimination test was composed of three sub-tests in 
approximate isoluminance conditions concerning the masking surrounding pattern of 
squares with randomly varying luminance, and dots (reference and target) moved at the 
same velocity (5 deg/s). We computed all cone contrast relative coordinates at the 
selected luminance interval near 30 cd/m
2
 with an error up to 2 cd/m
2
 (transformed 
using human cone spectral sensitivities (Stockman and Sharpe, 2000) at 10º), possible in 
this monitor display (relative LMS coordinates assume that display’s maximum white 
corresponds to LMS coordinate (1.0,1.0,1.0)). From this approximate isoluminance 
cone contrast relative coordinates selection we build one table, and from this table we 
select the same gray “colorless” coordinate to be our reference dot for all three tests, 
with an LMS cone contrast relative coordinate (0.4106,0.4108,0.4241). To further avoid 
the use of residual luminance cues, we adopted the noise luminance strategy (Regan et 
al., 1994; Barbur et al., 1994; Pacheco-Cutillas et al., 1999; Castelo-Branco et al., 
2004). In short, the addition of luminance noise ensures that only chrominance cues can 
be used. Residual luminance cues were avoided by placing a matrix of luminance noise 
around each dot. This matrix was composed of twelve 0.3º squared dots, with six 
different luminance noise levels (30, 34, 38, 42, 46 or 48 cd/m
2
), the luminance of each 
dot randomly changed during the trial (synchronized to the screen refresh rate). In 
summary, given the inherent limitations of conventional hardware, we aimed at the use 
of color cues using luminance noise, and computed all colors at a luminance near 30 
cd/m
2
 +/- 2 cd/m
2
. We did not aim to go above 30 cd/m
2
 to ensure adequate color output 
range across channels. This error was masked with squares with different luminances.  
We then developed three (relatively) biased cone contrast relative coordinates 
stimulation tests. For example, concerning the L-cone test, its stimulation exceeds the 
M-cone stimulation and at the same time we fix the S-cone stimulation value; the 
reverse happens in M-cone test, where M-cone stimulation exceeds L-cone stimulation 
value, whereas the S-cone remains fixed (for instance, a variation of 15% in one cone 
produced a reciprocal variation of 2.5% in the other cone). In the S-cone test, we fix L-
Cone and M-cone stimulation value, and vary only the S-cone relative contrast 
coordinate. The target dot starting point for each test was L-cone test (l=0.4732), M-
cone test (m=0.5158), S-cone test (s=0.9). These appeared like a pale red, green and 
purple dot, respectively. Maximum and minimum step size in the staircase procedure 
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for the L, M, S-cone tests were 0.1 dB / 0.001 dB, 0.1 dB / 0.001 dB and 0.4 dB / 0.08 
dB. The subject was asked “Which dot has color?” and answered either “Left/Right” 
(for the horizontal meridian) or “Up/Down” (for the vertical and oblique meridians). 
 
 
3.1.2 ELECTROPHYSIOLOGY 
3.1.2.1 PATTERN ELECTRORETINOGRAM 
 
We recorded pattern electroretinogram (PERG; RETIport32, Roland Consult, 
Germany), which provides information about macular and ganglion cell function, 
following the ISCEV standards (Bach et al. 2013) and using DTL fiber as recording 
electrodes. The stimulus consisted in a reversal black and white checkerboard pattern 
(4.3 reversals per second, rps), with a contrast of 97% and a check size of 0.74º. The 
stimulus was presented binocularly at a 20-inch monitor (frame rate: 60 Hz), at a 
viewing distance of 1 meter. Observers were instructed to fixate a small red cross in the 
center of the screen and the fixation was checked by means of online video-monitoring 
during recording sessions. Refractive errors were corrected for the test distance, when 
applicable.  
The active voltage range of bioelectrical signal was ±100 μV. Signals were 
amplified with a gain of 100,000 and bandpass filtered (1-100 Hz). We collected 200 
artefact-free sweeps to obtain an average waveform (artifact rejection level of 5%). To 
confirm reproducibility, two PERG measurements were taken (Figure 3.4). Finally, the 
amplitudes (μV) and peak time values (ms) of responses for each P-50 and N-95 
components and also the PERG ratio (N-95 amplitude divided by P-50 amplitude) were 
analyzed.  
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Figure 3.4. A Pattern ERG recorded in a healthy eye [a and b, first and second measurement]. 
 
 
 
3.2 STRUCTURAL ASSESSMENT 
3.2.1 SPECTRAL-DOMAIN OPTICAL COHERENCE 
TOMOGRAPHY 
 
OCT has histology-level resolution, given the optical accessibility of the retina. 
In this study, we have used Spectralis SD-OCT software version 5.3.2 (Heidelberg 
Engineering, Heidelberg, Germany) to obtain peripapillary RNFL and retinal thickness 
(RT) measurements (Laguna et al. 2013). Image acquisition was performed in high-
speed mode, providing an axial resolution of 7 μm and a transversal resolution of 14 
μm.  
 
Peripapillary RNFL thickness 
 
Concerning RNFL measurements, a circular 3.5 mm scan centered on the optic 
nerve head was used (768 A-scans) and a peripapillary RNFL thickness sectors were 
evaluated (temporal [315º - 45º], superior [45º - 135º], nasal [135º - 225º], and inferior 
quadrant [225º - 315º]).  
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Macular thickness 
 
We also obtained cross-sectional images centered on the macula, scanning a 
20ºx20º pattern, with 25 horizontal raster scans (distance between B-scans: 245 μm) and 
512 A-scans (ART mode: 20 images averaged). Macular retinal thickness was 
calculated by computing the distance between the signal from vitreoretinal interface and 
the signal from basement membrane of the retinal pigment epithelium (RPE), Bruch’s 
membrane complex. We used the RT map analysis protocol, which displays retinal 
thickness in nine ETDRS subfields. For analysis three rings were considered: ring 1 
(central circle with 1 mm of diameter), ring 2 (3 mm) and ring 3 (6 mm). 
 
IRL, ORL and macular RNFL thickness 
 
Inner retinal layer (IRL) thickness measurements (including nerve fiber layer, 
ganglion cells layer, inner plexiform layer and inner nuclear layer) were also determined 
through manual segmentation (Aaker et al. 2010). This was accomplished using 
Heidelberg software by setting the inner limit of the IRL at the internal limiting 
membrane, and the outer limit at the outer border of the inner nuclear layer (see Figure 
3.5). We also performed a manual segmentation of macular RNFL thickness (first layer 
of IRL). Subtracting IRL thickness from the global retinal thickness, we obtained Outer 
retinal layer (ORL) (including outer plexiform layer, outer nuclear layer, outer limiting 
membrane, layer of rods and cones and RPE). For IRL, ORL and macular RNFL 
analysis, we also considered the 3 rings described above. 
 
 
 
Figure 3.5. Spectral domain OCT image of a section through the fovea of the right eye of a control 
subject showing the segmented inner retinal layer (IRL) (red lines). The following layers of the IRL are 
shown: retinal nerve fiber layer (RNFL), ganglion cell layer (GCL), inner plexiform layer (IPL) and inner 
nuclear layer (INL). 
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3.2.2 MAGNETIC RESONANCE IMAGING 
 
The magnetic resonance imaging (MRI) data was acquired in a 3T scanner 
(Siemens Magnetom TrioTim 3T, Erlangen, Germany) at the Portuguese Brain Imaging 
Network, with a 12 channel head coil (d’Almeida et al. 2013). For each participant we 
obtained two 9-minute long T1-weighted three-dimensional Magnetization Prepared 
Rapid Acquisition Gradient Echo (MPRAGE) sequences, repetition time (TR) 2.3 s, 
echo time (TE) 2.98 ms, flip angle (FA) 9º, field of view (FoV) 256x256 mm
2
,  yielding 
160 slices with 1x1x1 mm
3
 voxel size; and also four functional runs (three polar angle 
and one eccentricity stimuli)  using single shot echo planar imaging (EPI) acquired in 
the axial plane orthogonal to the anterior commissure covering the occipital, temporal 
and frontal cortices, TR 2 s, TE 39 ms with a 128x128 imaging matrix, interslice time 
76 ms, FA 90º, FoV 256x256 mm
2
, yielding 26 slices with 2x2x2 mm
3
 voxel size. 
The stimuli presented consisted in a polar angle encoding paradigm comprised 
by a rotating (anticlockwise) black and white checkered wedge flickering at 8 Hz (48s 
full cycle, 4 cycles/scan, three scans per subject); and an eccentricity mapping 
paradigm, using an expanding black and white checkered ring flickering at 8 Hz (48s 
each full expansion, 4 expansions/scan, one scan per subject), while the subject was 
instructed to fix an orange-colored central point (Figure 3.6). The stimuli spanned 
23ºx23º of visual angle (diameter).  
 
 
 
Figure 3.6. Schematic illustration of visual stimuli for functional MRI: (A) polar angle paradigm - 
rotating wedges revolving 360º anticlockwise around the fixation point and (B) eccentricity paradigm - 
expanding ring outward from the fixation point. 
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All image processing, cortical thickness and retinotopic mapping was performed 
with BrainVoyager QX 2.2 (Brain Innovation, Maastricht, The Netherlands). Thickness 
values of each visual area were extracted with BVQX toolbox for MATLAB (R2008a, 
v.7.6.0, The MathWorks, USA). 
Basically, cortical thickness (CT) was measured through a process that involves 
four essential steps: 1) high-quality segmentation of the inner and outer cortex boundary 
of the preprocessed high quality T1-weighted anatomical 3D data sets. The two 
anatomical datasets were averaged to get a higher signal-to-noise ratio and then 
normalized to the Talairach coordinate space; 2) cortical thickness measurement in 
volume space by the Laplace method (Jones et al. 2000); 3) cortical thickness 
measurement in surface space in order to profit from cortical alignment, over inflated 
meshes; 4) cortical thickness analysis for regions-of-interest (ROIs) delineating patches-
of-interest based on color coding of polar angle and eccentricity experiments (see Figure 
3.7 for an example of cortical thickness map).   
 
 
 
Figure 3.7. Thickness map over inflated and flattened meshes (right hemisphere of a control subject). The 
color-scale map ranges from 0.5 mm (dark blue) to 6 mm (green). 
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The eccentricity and polar angle gradients define visual field sign maps that 
reflect the mirrored representation of visual areas (Sereno et al. 1994). Hence, we 
obtained two-color code map that established the lateral boundaries of the cortical visual 
areas. Retinotopic areas V1, V2 and V3 were manually defined over flattened meshes 
for each subject in each hemisphere using Brainvoyager’s surface drawing tools (Figure 
3.8). Obtained ROIs were used as “masks” to the analysis of regional cortical thickness. 
 
 
 
Figure 3.8. Retinotopic mapping on inflated and flattened meshes (right hemisphere of a control subject): 
(A) polar angle paradigm; (B) eccentricity paradigm and (C) Delineating early visual areas as regions-of-
interest based on color coding of polar angle and eccentricity experiments. 
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CHAPTER 4 
 
GENETICALLY INDUCED IMPAIRMENT OF  
RETINAL GANGLION CELLS IS LINKED TO  
EXTRASTRIATE CORTICAL PLASTICITY 
 
 
4.1 SUMMARY 
 
Leber hereditary optic neuropathy (LHON) is a maternally inherited 
mitochondrial disorder, which leads to initially silent visual loss due to RGC 
degeneration. The major aim of this study was to establish a link between features of 
silent retinal progressive impairment and cortical reorganization in a cohort of 15 
asymptomatic patients harboring the 11778G>A mutation with preserved visual acuity 
and normal ocular examination (pre-clinical phase). Most of these patients showed a 
visual field with a constant pattern of a paracentral defect. To study plasticity evoked by 
clinically silent degeneration of RGC we only studied mutation carriers.  
We phenotyped pre-clinical silent degeneration from the psychophysical, 
neurophysiological and structural points of view to understand whether retinal measures 
could be related to cortical reorganization, using pattern electrophysiology (RGC 
function was studied), chromatic CS along three chromatic axes and OCT to measure 
macular, RGC nerve fiber layer as well as inner and outer retinal layer thickness. We 
then performed correlation analysis of these measures with cortical reorganization as 
assessed by cortical magnetic resonance imaging (MRI) thickness measures in 
retinotopically mapped (using functional MRI) extrastriate visual cortex. We found that 
compensatory cortical plasticity occurring in V2 and V3 is predicted by thickness of 
macular RGC axonal layer. This was also the most discriminative measure between 
carriers and controls, as revealed by ROC curve analysis. Moreover we found that the 
substantial cortical reorganization that occurs in the carrier state can be used to provide 
statistical discrimination between carrier and normal groups to a level that is similar to 
measures of retinal dysfunction.  
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We conclude that cortical compensatory plasticity in visual areas V2 and V3 is 
triggered by pathology in RGC axons.  
 
 
 
4.2 INTRODUCTION 
 
Leber hereditary optic neuropathy (LHON) is a maternally inherited disease 
associated with mtDNA pathogenic point mutations (Carelli et al., 2007). This optic 
neuropathy is the most frequent mitochondrial disorder (Chinnery et al., 2002) and in 
over 90% of cases it is due to three mtDNA point mutations, respectively at position 
11778G>A, 14484T>C and 3460G>A, affecting complex I subunit genes of the 
mitochondrial respiratory chain (Mackey et al., 1996; Man et al., 2002; Newman, 2005). 
LHON leads to degeneration of RGC and their axons in the optic nerve, with a selective 
loss of the smaller-caliber fibers of the papillomacular bundle in early disease stages 
(Sadun et al., 2000; Carelli et al., 2004).  
In a pre-clinical phase, swelling of retinal nerve fiber layer (RNFL) may occur 
(Carelli et al., 2004; Yu-Wai-Man et al., 2009) as objectively documented by OCT. In 
this sense, unaffected carriers (pre-clinical phase) may show a thickened RNFL in 
temporal and inferior quadrants (Savini et al., 2005). On psychophysical testing, these 
also show evidence for subtle impairment of optic nerve function, as assessed by 
chromatic and achromatic CS (Quiros et al., 2006; Sadun et al., 2006; Ventura et al., 
2007).  
After clinical onset, the RNFL gradually degenerates and the endpoint is usually 
optic atrophy with permanent severe loss of central vision and relative sparing of 
papillary light responses (Carelli et al., 2004). A few studies using magnetic resonance 
(MR) spectroscopy have found a non selective and isolated involvement of the optic 
nerve and reported an abnormal mitochondrial energy metabolism in the occipital lobe 
of clinically affected patients (Cortelli et al., 1991; Barbiroli et al., 1995; Lodi et al., 
2002). Using voxel-based morphometry (VMB), Barcella et al. (2010) have described a 
significant reduced grey matter volume in bilateral primary visual cortex, and reduced 
white matter volume in optic chiasm, optic tract and areas located in optic radiations, in 
LHON patients in well established retinal degeneration and clinical symptoms.  
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Interestingly, in the pre-symptomatic stage cortical thickness may actually be 
increased (d’Almeida et al., 2013), suggesting early compensatory plasticity that is lost 
when the disease becomes clinically established. Cortical plasticity is here defined as 
the capacity of the brain to adapt to changing demands by altering its structure (Lövdén 
et al., 2010; Lövdén et al., 2013). Recent studies have established a link between 
structural brain plasticity and changes in cortical thickness (Engvig et al., 2010; Lövdén 
et al., 2013). In that study, we used magnetic resonance imaging (MRI) to measure 
cortical thickness and functional MRI retinotopic mapping to define functionally 
cortical visual areas V1, V2 and V3 in unaffected mutation carriers (pre-clinical phase). 
We found that cortical thickness, in particular in extrastriate regions (V2, V3), was 
significantly higher in LHON carriers as compared to age-matched controls.  
The major aim of this study was to test whether a link can be established 
between RGC impairment in Leber optic neuropathy and such cortical compensatory 
plasticity in extrastriate cortex. All our selected patients were mutation carriers (pre-
clinical phase). Therefore, RGC degeneration is present, affecting their visual function, 
such as chromatic CS. 
In summary, we analyzed the visual and cortical phenotype of asymptomatic 
genetically characterized LHON patients (unaffected carriers from the same pedigree) 
which also allowed to compare retinal and cortical markers in statistical classification of 
the LHON carrier status. We found that the RNFL status predicts cortical plasticity, as 
assessed by correlation analysis.  
 
 
 
4.3 METHODS 
 
4.3.1 PARTICIPANTS 
 
A cohort of 15 asymptomatic LHON carriers from two generations of the same 
pedigree (mean age ± SD = 29.2 ± 13.4 years; age range [8-47]) was included in the 
study and was compared with a gender and age-matched control group (n = 24; mean 
age ± SD = 31.3 ± 13.5 years; age range [7-54]). Asymptomatic LHON patients 
underwent genetic analysis and the presence of mtDNA 11778G>A mutation was 
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confirmed in all family members (homoplasmic in eleven and heteroplasmic in four 
participants) (demographic characteristics are summarized in Table 4.1). 
All participants were submitted to a complete ophthalmological examination, 
including best-corrected visual acuity (VA; decimal scale), slit lamp biomicroscopy, 
ocular tension measurement (Goldmann applanation tonometer) and fundus 
examination (Goldman lens). LHON carriers presented a normal ocular examination, 
good visual acuity (mean ± SD = 1.1 ± 0.1) and no fundus changes. In spite of the 
absence of a clinical diagnosis, visual field deficits were found. According to Octopus 
v311 normative database, we found 6 normal visual fields (20% of the total sample); the 
remaining 80% showed a mean defect (MDf) and/or a loss variance (LV) outside the 
normal range, with a constant pattern of paracentral defects (see Table 4.1 and Figure 
4.1 for representative visual field defects). 
  Exclusion criteria included retinal and neurological diseases, diabetes even in the 
absence of retinopathy, significant media opacities, pseudophakic and aphakic eyes, and 
high ammetropies (sphere > ± 4D; cylinder > ± 2D). 
This study and all procedures were reviewed and approved by the Ethics 
Commissions of the Faculty of Medicine of the University of Coimbra (Comissão de 
Ética da Faculdade de Medicina da Universidade de Coimbra) and were conducted in 
accordance with the Declaration of Helsinki. Written informed consent was obtained 
from participants older than 18 years of age and from parents/ guardians in the case of 
participants younger than 18 years of age and procedures of the study were fully 
explained. 
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Table 4.1. Demographic characteristics and clinical data of LHON carriers group. 
 
Patient mtDNA 
11778G>A 
Mutation 
Heteroplasmic 
mutational 
load (%) 
Age 
(years) 
Gender Visual 
Acuity 
RE/LE 
Visual 
Field 
MDf (dB) 
RE/LE 
Visual 
Field 
LV (dB
2
) 
RE/LE 
1 homoplasmic  47 M 1.2 1.2 -0.7 0.7 3.8 3.3 
2 heteroplasmic 80.6 46 F 1.0 1.0 1.8 1.7 5.2 4.4 
3 homoplasmic  43 F 1.0 1.0 2.8 3.8 4.9 10.3 
4 homoplasmic  41 M 1.2 1.2 4.2 4.0 4.0 8.3 
5 homoplasmic  40 F 1.0 1.0 4.0 4.4 3.1 6.6 
6 homoplasmic  39 F 1.0 1.0 5.0 3.8 2.1 7.9 
7 homoplasmic  37 F 1.2 1.2 1.8 0.9 5.2 5.1 
8 heteroplasmic 78.8 30 F 1.2 1.2 7.0 7.8 10.8 9.1 
9 heteroplasmic 78.0 21 M 1.2 1.2 5.5 7.8 32.3 40.4 
10 homoplasmic  22 F 1.2 1.2 3.9 6.6 9.2 26.7 
11 homoplasmic  17 M 1.2 1.2 3.3 5.0 10.9 24.1 
12 homoplasmic  19 M 1.0 1.2 2.8 5.2 10.5 15.2 
13 homoplasmic  10 M 1.0 1.0 4.1 6.9 6.3 13.7 
14 heteroplasmic 67.0 18 F 1.2 1.2 7.8 7.6 9.2 6.7 
15 homoplasmic  8 M 1.0 1.2 3.1 3.1 9.9 7.9 
 
Note: M = male; F = female; RE = right eye; LE = left eye; MDf = mean defect; LV = loss variance 
 
 
4.3.2 FUNCTIONAL ASSESSMENT 
 
In this study, LHON carriers group and controls performed the following 
psychophysical and electrophysiological methods: 
- Standard automated perimetry (Octopus version 311, Haag-Streit AG, 
Germany); 
- Chromatic contrast sensitivity psychophysical test (CCT; Cambridge 
Research Systems Lda., CRS, Rochester, UK); 
- Pattern electroretinogram (PERG; RETIport32, Roland Consult, Germany). 
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Figure 4.1. Representative visual field perimetric maps (color maps depict decibel scale) of LHON 
carriers. Note a constant pattern of a paracentral defect in visual fields with a relatively preserved 
sensitivity of central locations as illustrated in the cumulative defect curves. 
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4.3.3 STRUCTURAL ASSESSMENT 
 
We have used a Spectralis SD-OCT software version 5.3.2 (Heidelberg 
Engineering, Heidelberg, Germany) to obtain peripapillary RNFL and macular 
thickness measurements. Through manual segmentation, we also determined the inner 
retinal layer (IRL), outer retinal layer (ORL) and macular RNFL thickness. 
All patients and controls have also performed a Magnetic resonance imaging 
experience. The MRI data was acquired in a 3T scanner (Siemens Magnetom TrioTim 
3T, Erlangen, Germany). 
 
For detailed methods see Chapter 3 – Methodological overview. 
 
 
4.3.4 STATISTICAL ANALYSIS 
 
Statistical analysis was performed using statistical software packages (SPSS 
version 19.0 - SPSS Inc., Chicago, IL; and StatView - SAS, Cary, NC, USA). After 
verifying statistical assumptions using Shapiro-Wilk normality check and Levene 
homogeneity tests, comparisons between means were performed with multivariate 
General Linear Model based on Wilk’s Lambda, with Sidak’s adjustment for multiple 
comparisons. To prevent biases caused by violations of independence, we used the 
mean value of both eyes for all variables, since a significant interocular correlation was 
found (for control and LHON carrier groups). For cortical thickness analysis (each 
hemisphere was considered individually), age was setting as covariate (d’Almeida et al. 
2013). Pearson coefficient was used for correlation analyses. 
The Receiver Operating Characteristic (ROC) curve analyses were also 
performed using MedCalc version 12.2.1.0 (MedCalc Software, Mariakerke, Belgium) 
to determine sensitivities at a fixed specificity (approximatey 80%) for all tested 
parameters. The relative diagnostic accuracies of functional and structural tests were 
assessed by comparing areas under the ROC curves (AUC). Statistically significant 
differences between AUC were determined using the method of DeLong et al. (1988). 
Results with p<0.05 were considered statistically significant.  
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4.4 RESULTS 
 
Evidence for impairment of Parvo and Koniocellular contrast sensitivity  
 
We found a significant group effect on chromatic CS [F(3,21)=3.876, p=0.024, 
  
 =0.356]. Chromatic thresholds were significantly higher in LHON carriers for protan 
(red) (p=0.008), deutan (green) (p=0.016) and tritan (blue) (p=0.010) axes, as compared 
to control participants (Figure 4.2).  
 
 
 
Figure 4.2. Chromatic contrast sensitivity thresholds. Significant impairment is observed for the three 
chromatic axes in patients. Note that higher chromatic thresholds are related to lower contrast sensitivity. 
 
 
Assessment of RGC function using the pattern electroretinogram (PERG) 
 
Surprisingly, we found a marginally significant group effect on PERG waves 
amplitude [F(2,23)=3.200, p=0.059,   
 =0.218]. Higher amplitudes of P-50 (p=0.047) and 
N-95 (p=0.017) waves were found in LHON carriers, as compared to the control group 
(Figure 4.3; see also a representative example in Figure 4.4A). Implicit time of both 
waves was normal, as well as N-95/P-50 ratio. 
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Figure 4.3. Ganglion cell function assessed by pattern ERG. LHON carriers show surprisingly higher 
amplitudes of P-50 and N-95 components of PERG than control group.  
 
 
 
Figure 4.4. PERG plots (A), OCT – peripapillary RNFL (B) and OCT - retinal thickness (C) maps of a 
representative LHON carrier (#10) and a control subject. Note that carrier #10 presents an increase in 
amplitudes of both P-50 and N-95 waves [a and b, first and second measurement] (A), an increase in 
peripapillary RNFL thickness (B) and decreased retinal thickness (more evident in the most central rings) 
(C), as compared to the control. 
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Evidence for early swelling of papillomacular RNFL bundle  
 
A significant group effect was not found on peripapillary RNFL thickness 
[F(4,19)=2.364, p=0.090,   
 =0.332]. However, LHON carriers showed an increased 
RNFL thickness, which was significant for inferior (p=0.009) and temporal (p=0.027) 
quadrants (see Figure 4.5A and Figure 4.4B for a representative example of increased 
RNFL thickness in Leber carriers group).  
 
 
 
Figure 4.5. Pathophysiological RNFL swelling as an early change in LHON carriers. Peripapillary RNFL 
(inferior and temporal quadrants) (A) and macular RNFL thickness (ring 3) (B) are significantly increased 
in the LHON carrier group, comparing with controls. 
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Inner retinal layer, Macular retinal nerve fiber layer and Outer retinal layer 
thickness measured using Spectral Domain-OCT 
 
We found a significant group effect on global macular thickness [F(3,20)=9.066, 
p=0.001,   
 =0.576] and ORL thickness [F(3,13)=3.246, p=0.057,   
 =0.428]. By the other 
hand, a group effect was not found for IRL and macular RNFL thickness.  
Analysis by rings showed a significant decrease in global macular thickness for 
the most central rings [ring 1: p=0.013; ring 2: p=0.017] (Figure 4.6; Figure 4.4C, 
representative example of retinal thickness of LHON carrier and control groups). 
We also found a decrease in outer retinal layer thickness for the most central 
rings [ring 1: p=0.005; ring 2: p=0.017], unlike the inner retinal layer that showed no 
differences between carriers and controls. On the other hand, we found the expected 
increase (due to the known pathophysiological swelling) in macular RNFL thickness 
(most peripheric ring) in Leber carriers [ring 3: p=0.044] (Figure 4.5B). 
 
 
 
 
Figure 4.6. Retinal thickness assessed by SD-OCT. Macular thickness (most central rings) are 
significantly decreased in Leber carriers. 
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Cortical thickness of retinotopically defined visual areas using functional magnetic 
resonance imaging 
 
Mean cortical thickness was calculated as the average of all vertices inside each 
functionally defined visual area V1, V2 and V3 from each subject hemispheres 
(d’Almeida et al., 2013).  
We found a significant group effect on mean cortical thickness [F(3,47)=3.156, 
p=0.0335,   
 =0.213]. LHON carriers had higher values of visual cortical thickness than 
controls, significant for V2 (p=0.0038) and V3 (p=0.0211) (age was setting as 
covariate) (Figure 4.7; see also Figure 4.8 for a representative example of cortical 
thickness of both groups). Figure 4.9 shows preserved functional retinotopic data 
confirming that we were indeed studying the cortical impact of subtle RGC functional 
and structural loss. 
 
 
 
Figure 4.7. LHON carriers show an increased cortical visual areas thickness, being significant for V2 and 
V3. 
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Figure 4.8. Representative cortical thickness map (in mm) of a LHON carrier #10 (A) and a control 
subject (B) as assessed by Magnetic Resonance Imaging. Note the higher cortical thickness values 
observed in Leber carrier patients in visual cortex. 
 
 
 
 
Figure 4.9. Representative functional retinotopic data of a LHON carrier #1 (A) and a control subject (B). 
These data show that retinotopic maps are intact despite the relative peripheral visual loss (LH, left 
hemisphere; RH, right hemisphere).  
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Correlation analyses for LHON carriers group 
 
Significant correlations between retinal and cortical measures were found for 
asymptomatic LHON group: Macular RNFL thickness (ring 3) correlated positively 
with V2 (r=0.712, p=0.0075) and V3 (r=0.706, p=0.0083). These specific correlation 
patterns were not found in controls and were not observed for other measures.  
 Although we have not found a significant correlation between visual field 
measures and cortical data, we found a correspondence between the visual fields that 
showed the lowest sensitivity values for the most peripheral ring and highest cortical 
thickness values of extrastriate visual areas. We tested the consistency of this finding, 
by using median separation criteria, whether relative peripheral visual field loss was 
associated with increased extrastriate thickness. The proportion of concordant pairs was 
significantly larger than discordant pairs (p=0.004, binomial test). 
 We also found that the central ring of visual field correlated positively with the 
central ring of global macular thickness (r=0.601, p=0.0160) and with the central ring of 
ORL thickness (r=0.604, p=0.0360). 
 
ROC Curve – Sensitivity/Specificity analysis 
 
ROC sensitivity curves were generated for all included tests. At approximately 
80% specificity, the highest sensitivities were found for OCT macular RNFL ring 3 
(83%; cut-off: 46.25 µm); OCT outer retinal layer (75% for all rings; cut-off ring 1: 
200.5 µm, ring 2: 180.25 µm, ring 3: 162 µm); OCT peripapillary RNFL inferior 
quadrant (73%; cut-off: 141.5 µm) and also for CCT Protan (69%; cut-off: 50.2 u’v’ 
units) (for more details see Table 4.2).  
 
Classification accuracy of the mutation carrier state by Areas Under the ROC 
Curve (AUC) 
 
The AUC is an important measure that summarizes the diagnostic accuracy of 
each parameter. An AUC equal to 1 represents a perfect discrimination between healthy 
and mutation carrier groups, whereas an AUC of 0.5 represents chance discrimination. 
In our study, we found AUCs up to 0.903 (Table 4.2). The parameters that showed 
higher AUC value were macular RNFL ring 3 (AUC=0.903, p<0.0001), outer retinal 
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layer ring 1 (AUC=0.854, p=0.0001), CCT Protan (AUC=0.823, p<0.0001) and 
peripapillary RNFL inferior quadrant measures (AUC=0.800, p=0.0007).  
 
 
 
 
Table 4.2. Areas under the receiver operating characteristic (ROC) curve (AUC) and associated 95% 
confidence interval (CI) are presented for CCT, PERG, OCT and MRI parameters. Sensitivities obtained 
for each parameter at approximately 80% specificity, and criterion values used for that specificity are also 
presented. 
 
Parameters AUC 95% CI p_value Sensitivity/ 
Specificity (%) 
Criteria for 
80% Specificity 
CCT      
Protan 0.823 0.633, 0.940 <0.0001 69/80 50.2 
Deutan 0.774 0.578, 0.909 0.0023 38/80 59.5 
Tritan 0.792 0.598, 0.921 0.0012 38/80 76.95 
PERG      
P-50 amp 0.710 0.512, 0.862 0.0325 53/82 3.48 
N-95 amp 0.743 0.548, 0.886 0.0111 53/82 4.93 
N-95/P-50 ratio 0.595 0.398, 0.772 n.s. 40/83 1.56 
P-50 IT 0.510 0.318, 0.699 n.s. 13/83 52 
N-95 IT 0.564 0.369, 0.746 n.s. 27/79 96 
OCT      
Peripapillary RNFL sup 0.597 0.392, 0.780 n.s. 47/83 128.5 
Peripapillary RNFL inf 0.800 0.602, 0.928 0.0007 73/83 141.5 
Peripapillary RNFL nasal 0.694 0.489, 0.856 n.s. 40/83 85 
Peripapillary RNFL temp 0.789 0.590, 0.921 0.0021 67/83 75.5 
RT ring 1 0.775 0.574, 0.912 0.0026 67/83 272.5 
RT ring 2 0.744 0.541, 0.891 0.0137 67/83 336.5 
RT ring 3 0.508 0.310, 0.704 n.s. 27/83 290.13 
RT sup 0.589 0.384, 0.773 n.s. 33/83 316.75 
RT inf 0.606 0.400, 0.787 n.s. 47/83 312.5 
RT nasal 0.656 0.449, 0.826 n.s. 47/83 325.5 
RT temp 0.697 0.491, 0.858 n.s. 60/83 302.75 
IRL ring 1 0.635 0.394, 0.835 n.s. 42/85 67 
IRL ring 2 0.729 0.487, 0.900 n.s. 58/85 155 
IRL ring 3 0.573 0.336, 0.788 n.s. 42/85 145.5 
ORL ring 1 0.854 0.626, 0.970 0.0001 75/85 200.5 
ORL ring 2 0.786 0.548, 0.935 0.0099 75/85 180.25 
ORL ring 3 0.781 0.543, 0.932 0.0174 75/85 162 
Macular RNFL ring 1 0.507 0.266, 0.746 n.s. 50/83 5 
Macular RNFL ring 2 0.583 0.332, 0.806 n.s. 42/83 29.5 
Macular RNFL ring 3 0.903 0.671, 0.990 <0.0001 83/83 46.25 
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MRI      
V1 0.608 0.462, 0.740 n.s. 40/82 2.40 
V2 0.673 0.529, 0.796 0.0308 30/82 2.53 
V3 0.706 0.563, 0.824 0.0136 33/82 2.49 
 
Note: CCT = cambridge color test; PERG = pattern electroretinogram; OCT = optical coherence 
tomography; MRI = magnetic resonance imaging; RNFL = retinal nerve fiber layer; RT = retinal 
thickness; IRL = inner retinal layer; ORL = outer retinal layer; amp = amplitude; IT = implicit time; sup = 
superior; inf = inferior; temp = temporal; n.s. = not significant. 
 
 
 
4.5 DISCUSSION 
 
In this study, we established for the first time, a link between early RGC 
impairment at the axonal level (RNFL) in unaffected LHON carriers (mtDNA 
11778G>A point mutation) and cortical compensatory plasticity in extrastriate cortex. 
Although we found cortical thickness changes specifically in extrastriate areas V2/V3, 
primary visual cortex actually tend to follow the same trend, but with a much smaller 
effect size. The novelty of our work is therefore that plasticity can occur even during 
clinically silent degeneration of RGC, and importantly, in the presence of relative 
peripheral visual loss, although retinotopic maps are intact. Interestingly, retinal and 
cortical biological markers can determine the presence of LHON carrier status, as 
measured by ROC analysis, suggesting that they are tightly coupled.  
LHON carriers showed the expected RNFL swelling that is a pathophysiological 
marker of early damage in this condition, in particular for temporal and inferior 
quadrants (Savini et al., 2005). Since these patients show absence of leakage around the 
disk on fluorescein angiography (Smith et al., 1973; Nikoskelainen et al., 1996; 
Newman, 2005), the RNFL swelling corresponds to a pseudoedema. This 
pseudoedematous RNFL swelling is probably a consequence of impaired axoplasmic 
transport and compensatory increase of mitochondrial biogenesis (Barboni et al., 2010). 
Our findings are consistent with vulnerability of small axons of papillomacular bundle 
in a pre-clinical stage of this disease (Sadun et al., 2000). Taking into account that the 
thin RGC related papillomacular bundle is the anatomical substrate for color vision 
(Sadun et al., 2000; Carelli et al., 2004), this is consistent with the observation that 
parvo and koniocellular impairment occurs even in asymptomatic carriers before the 
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massive death stage and conversion to the acute stage (Sadun et al., 2006; Ventura et al., 
2007).  
We also found that global macular thickness was decreased, at the cost of the 
surprising and significant decrease in the outer retinal layer, suggesting that damage at 
the pre-ganglion level also occurs in the LHON carrier status. Our functional 
neurophysiologic correlates of RGC function (PERG) showed surprising response 
augmentation that was independent from the changes in RGC related layers (RNFL and 
IRL). In a previous study (Laguna et al., 2013) in Down syndrome (DS) and a trisomic 
mouse model of DS (Ts65Dn), we found that abnormally high responses may occur in a 
retina with abnormal cellularity at the RGC level. A recent study (Guy et al., 2014) 
reported a progressive decrease of PERG amplitude in asymptomatic Leber subjects. 
Since the physiology of pre-clinical stages may widely differ from after disease onset, 
future evaluations of these patients should be conducted in order to assess the RGC 
function over preclinical period until conversion to clinical stage. 
Notably, we found that significantly increased cortical thickness measures (in 
particular in extrastriate cortex) in asymptomatic carriers (d’Almeida et al., 2013), were 
correlated with swelling of the macular RGC axons at the most peripheral ring. In other 
words, compensatory cortical plasticity occurring in V2 and V3 may be predicted by 
afferent changes in the thickness of RGC axonal layer (as measured by the segmented 
macular RNFL). This suggests that early retinal changes are reflected in retinotopically 
specific plasticity, as assessed by cortical thickness, which is a well established method 
to study structural plasticity (Kolb and Whishaw, 1998; Jiang et al., 2009; Engvig et al., 
2010; Lövdén et al., 2013). Our findings are specific and other cortical regions show 
unchanged thickness. 
It is relevant to point out that RNFL thickness was among the most sensitive 
classifiers of the mutation status (and with larger area under the ROC curve) further 
suggesting an important role in pre-clinical phases.  Furthermore, our cortical measures 
were at least as discriminative as some of the retinal outcomes, suggesting that visual 
cortical plastic changes and reorganization (d’Almeida et al., 2013) go well in parallel 
with subtle axonal pathology. Although the link of RNFL status with cortical plasticity 
was assessed by correlation analysis, given that information flows unidirectionally from 
the retina to the cortex we argue that this link is likely causal. 
We conclude that RGC impairment at the axonal level in Leber Optic 
Neuropathy carriers may trigger cortical compensatory plasticity in extrastriate cortex. 
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CHAPTER 5 
 
A NEW APPROACH TO ASSESS EARLY PROGRESSIVE LOSS 
ACROSS MULTIPLE VISUAL CHANNELS IN THE  
NATURAL HISTORY OF GLAUCOMA 
 
 
5.1 SUMMARY 
 
Glaucoma is a progressive optic neuropathy characterized by death of RGC with 
subsequent visual loss and visual field defect. In this study, distinct subsets of RGC 
populations were tested using three novel two-alternative forced choice psychophysical 
discrimination tests between two separated peripheral, small moving single dots at four 
distinct meridians. 
We aimed to evaluate the ability of new psychophysical tests, based on readily 
available hardware, to probe motion, achromatic and chromatic L, M and S cone 
contrast sensitivities, across the natural history of glaucoma. We assessed the sensitivity 
of these tests to detect functional damage at ocular hypertension stage, using ROC 
analysis. We also explored if eccentricity-related patterns of damage change with 
disease progression.   
We studied a cohort of 43 participants, recruited from the glaucoma consultation 
of the University Hospital of Coimbra, which were divided across different groups: 
ocular hypertension (n = 16 eyes; mean age [SD] = 65.24 [7.01] years; IOP > 21 
mmHg, normal visual field and optic disc), glaucoma suspects (n = 15; mean age [SD] = 
65.72 [10.71] years; normal visual field and optic disc changes) and primary open-angle 
glaucoma (n = 12; mean age [SD] = 68.79 [11.34] years; glaucomatous visual field 
defects and optic disc changes). These patients were compared with an age-matched 
group of controls (n = 15 eyes; mean age [SD] = 64.81 [8.24] years). 
All tests showed significant correlation with disease progression (mean Rho ± 
SD = 0.708 ± 0.075; p<0.0001) and had sufficient power to discriminated glaucoma 
subgroups. Most tests using this design had large sensitivity (above 90% for a 
specificity of at least 80%) to detect functional damage at the ocular hypertensive stage. 
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Disease related eccentricity-related patterns of damage were also found, matching the 
expected pattern of progression. So, we concluded that our new psychophysical 
discrimination tests are capable to probe disease progression and to detect functional 
damage at ocular hypertension stage. It is therefore possible to customize 
psychophysical test software to detect early changes and monitor disease progression, 
including progressive loss of functional reserve, using relatively simple hardware.  
 
 
 
5.2 INTRODUCTION 
 
Glaucoma comprises a group of optic neuropathies related to the death or 
dysfunction of RGC leading to progressive visual loss. It was estimated that, in 2010, 
60.5 million people had glaucoma, a figure which is expected to increase to 79.6 million 
in 2020 (Quigley and Broman, 2006). 
The diagnosis and evaluation of progression in glaucoma is classically based 
upon the identification of structural defects - caused by RGC death (Harwerth and 
Carter-Dawson, 1999; Yücel et al., 2003), namely the thinning of the retinal nerve fiber 
layer and the cupping of the optic nerve head – as well as functional defects (Harwerth 
et al., 2010). These range from de facto visual field loss, classically assessed by SAP, to 
decreases in visual performance that are recognized to occur even at a pre-SAP loss 
stage (Johnson et al., 1993; Maddess et al., 1999; Bagga et al., 2006).   
Such early functional defects depend on the relative degree of damage across the 
different central visual pathways for which two alternative hypotheses have been 
proposed. The preferential damage hypothesis states that glaucoma mainly targets large-
fiber RGC (Quigley et al., 1987; Quigley et al., 1988) which mainly belong to the 
magnocellular pathway (Maddess and Henry, 1992; Maddess et al., 1999; Shabana et 
al., 2003; McKendrick et al., 2010). However, there is now histological evidence of 
damage in all three major visual pathways (Yücel et al., 2003) – magnocellular, 
parvocellular and koniocellular – as well as psychophysical evidence of early damage in 
red-green and blue-yellow channel processing, which are related to the parvocellular 
and koniocellular pathways (Pearson et al., 2001; Castelo-Branco et al., 2004). These 
findings support the reduced redundancy hypothesis (Johnson, 1994). This postulates 
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that the increased sensitivity of certain tests (Sample and Weinreb, 1990; Castelo-
Branco et al., 2004; Fogagnolo et al., 2008) is explained by the stimulation of specific 
and therefore sparse subsets of ganglion cells, without the redundancy afforded by the 
other cell types. In other words, if a specific stimulus isolates a specific subset of 
ganglion cells, dysfunction of these cells will not be compensated due to lack of 
sufficient coverage. Therefore, even relative functional isolation of these ganglion cells 
types unmasks their smaller functional reserve (Anderson, 2006). Functional reserve is 
here defined as the amount of anatomical redundancy in terms of ganglion cell density 
in the retina and dendritic field overlap. Moreover, cell redundancy is also dependent on 
visual eccentricity, being lower in the periphery for all pathways (Silveira and Perry, 
1991; Carelli et al., 2004). Taking these physiopathological concepts into account, we 
developed new psychophysical paradigms that try to provide some degree of relative 
functional isolation of specific ganglion cell populations, by testing independent visual 
functions, in order to attempt to relate glaucomatous neural losses with the natural 
history of the disease, from early to late stages. To this purpose we created 
discrimination tests that use small, moving and peripheral pairs of single dots which are 
targets for independent motion, achromatic contrast and chromatic contrast 
discrimination tests.  
In summary, we aimed to evaluate the potential ability of novel tests to probe 
disease progression. We also assessed if these tests could detect functional damage at 
ocular hypertension stages, using sensitivity analysis. Finally, we also explored the 
putative relation between eccentricity and patterns of disease progression. 
 
 
 
5.3 METHODS 
 
5.3.1 PARTICIPANTS 
 
Forty-three patients recruited from the glaucoma consultation of the University 
Hospital of Coimbra were included in the study and were compared with an age-
matched group of controls (n = 15 eyes; mean age ± SD = 64.81 ± 8.24 years).  
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The clinical study sample consisted in 43 individuals in different stages of 
primary open-angle glaucoma
 
(European Glaucoma Society, 2008): ocular hypertension 
(HT; n = 16 eyes; mean age ± SD = 65.24 ± 7.01 years; VA = 0.81 ± 0.16; SAP MD = -
1.09 ± 0.84; C/D diameter = 0.36 ± 0.07), glaucoma suspects (GS; n = 15 eyes; mean 
age ± SD = 65.72 ± 10.71 years; VA = 0.83 ± 0.13; SAP MD = -1.01 ± 1.00; C/D = 
0.62 ± 0.08) and primary open-angle glaucoma (G; n = 12 eyes; mean age ± SD = 68.79 
± 11.34 years; VA = 0.85 ± 0.12; SAP MD = -4.62 ± 0.66; C/D = 0.68 ± 0.06). Only the 
dominant eye of each subject was tested. ANOVA showed no significant age difference 
between groups.  
Patients with primary open-angle glaucoma fulfilled the following criteria: C/D 
vertical diameter of 0.5 or more, MD visual field global index less than -2 dB (or <5% 
of confidence interval). Glaucoma suspects had C/D of 0.5 or more and normal visual 
fields (MD more than -2 dB or >5%, of confidence interval). Patients with HT showed 
an elevated IOP of 21 mmHg or more (on at least two occasions), without glaucomatous 
visual field defects (MD more than -2 dB or >5%, of confidence interval) or optic disc 
changes (C/D less than 0.5). 
All participants underwent a complete ophthalmic examination, including best 
corrected VA obtained with Snellen chart, Goldmann applanation tonometry (IOP 
measurement), slit lamp examination of the anterior segment, gonioscopy, retinal 
examination and optic disc evaluation. All individuals were also submitted to a visual 
field examination (white-on-white SAP) using the 30-2 standard program of Humphrey 
automated field analyzer (SITA-Fast strategy; HFA II, Carl Zeiss Meditec, Dublin, CA) 
(for details see Chapter 3 – Methodological overview). 
Exclusion criteria included the following: neuro-ophthalmologic diseases, retinal 
diseases, diabetes even in the absence of retinopathy, VA less than 0.6, known color 
vision disorders, pseudophakic and aphakic eyes, significant media opacities that 
preclude fundus examination, central corneal thickness outside normal range [540 ± 30 
µm (European Glaucoma Society, 2008)], and high ammetropy (sphere > ±4D; cylinder 
> ±2D). 
Informed consent was obtained from all subjects, in strict accordance with the 
institutional guidelines and approval of our local ethics committee and after explanation 
of the objectives of the study. The research was conducted in accordance with the tenets 
of the Declaration of Helsinki. 
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5.3.2 PSYCHOPHYSICAL METHODS 
 
We developed three novel 2AFC psychophysical tests that required the 
comparison and discrimination of a visual features (motion, achromatic contrast and 
chromatic contrast) between two separated moving single dots (a reference dot and a 
target dot, which were presented in opposite hemifields). 
 
For detailed psychophysical methods (set-up, general test features, staircase, 
motion discrimination test, achromatic contrast discrimination test and chromatic 
contrast discrimination test) see Chapter 3 – Methodological overview. 
 
 
5.3.3 STATISTICAL ANALYSIS 
 
Statistical analysis was performed using SPSS (IBM SPSS Statistics 21, IBM 
Corporation, NY, USA). After verifying the normality of the data across the study 
groups (Kolmogorov-Smirnov normality test), we used a parametric analysis (ANOVA 
between-group effects) for overall means comparison and Tukey HSD post-hoc test for 
multiple comparisons across groups. To study the effect of eccentricity within the same 
task performance, we used repeated measures ANOVA, with both main effects and 
linear trends adjusted to the least significant difference (LSD). We have also used a 
standard statistical measure of effect size (partial eta-squared,   
 ) (Cohen, 1992). 
Spearman coefficient was used to correlate psychophysical thresholds and ordered 
subject grouping categories. 
The Receiver Operating Characteristic (ROC) curve analyses were performed 
using MedCalc version 12.2.1.0 (MedCalc Software, Mariakerke, Belgium) to 
determine sensitivities at a fixed specificity (approximately 80%) for all tested 
parameters. The relative diagnostic accuracies of psychophysical tests were assessed by 
comparing areas under the ROC curves (AUC). Results with p<0.05 were considered 
statistically significant. 
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5.4 RESULTS 
 
Correlation of Psychophysical Performance with Stage 
 
We found that all of our new experimental measures strongly correlate with 
disease progression along stage defined by our study groups. Using Spearman Rank 
Correlation, a significant correlation between each and every psychophysical threshold 
and ordered subject grouping categories was found (mean Rho ± SD = 0.708 ± 0.075; 
p<0.0001 for all tests), revealing a distinct progressive visual performance profiling 
throughout the disease’s natural history. Figure 5.1, which shows percentile 
distributions of measured threshold and their progressive ranking across our study 
groups, exemplifies these results using one meridian (90º) as an example from each test. 
Similar results were observed for the other meridians. The highest correlation 
coefficient originated from the M-cone test at meridian 45º / 15º of eccentricity (Rho = 
0.820), while the lowest originated from the achromatic contrast test at meridian 0º / 
7.5º of eccentricity (Rho = 0.553). 
 
Despite our relatively small sample size, our effect sizes were large enough to 
perform group mean comparisons using ANOVA that revealed an overall significant 
difference between groups for every conducted test (p<0.0001 for every test except M-
cone test at meridians 90º and 135º, with p=0.014). We conducted a post-hoc analysis 
for pair-wise comparisons using Tukey HSD post-hoc test, which showed significant 
differences (p<0.05) for all tests at every meridian between the control group and each 
patient group, except for achromatic contrast [meridian 0º and meridian 45º: control vs 
ocular hypertensive and control vs glaucoma suspect; meridian 135º: control vs ocular 
hypertensive comparison] and chromatic contrast M-cone test [meridians 45º and 135º: 
control vs ocular hypertensive comparison was marginally significant]. Overall, these 
results further reinforce the strength of our new paradigms to distinguish between 
control and patient groups. In particular the general differences between control and 
ocular hypertensive groups are noteworthy. 
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Figure 5.1. Representative examples of percentile box plots obtained for study groups (control, C; ocular 
hypertensive, HT; glaucoma suspect, GS; and glaucoma, G). Only the meridian 90º is presented (similar 
results are observed for the others). Bars depict 10
th
 and 90
th
 percentiles, the top and bottom borders of 
the boxes represent the 25
th
 and 75
th
 percentiles, and the line segment inside the boxes depicts the median. 
Box plots show a clear visual performance ranking along the disease progression stages, represented by 
each study group. All correlations in the presented tests between psychophysical thresholds and stage 
defining study groups were significant with p<0.0001: (A) Rho=0.785, (B) Rho=0.672, (C) Rho=0.626, 
(D) Rho=0.768 and (E) Rho=0.756. 
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The Effect of Eccentricity in Task Performance 
 
Building on the fact that we repeated each test at different eccentricities, we also 
studied the effect of eccentricity on task performance. To this purpose, we used 
Repeated Measures ANOVA to assess if there were group related asymmetries of visual 
performance with increasing eccentricity and whether these asymmetries varied in a 
linear way. We studied this effect on the control, ocular hypertensive and glaucoma 
study groups and thresholds obtained at the 45º and 135º meridians (same eccentricity) 
were averaged. 
First of all, under the conditions of our tests there were no significant 
eccentricity dependent differences in task performance in the control group for every 
test (motion test – p=0.324; achromatic contrast test – p=0.880; L-Cone test – p=0.426; 
M-Cone test – p=0.332; S-Cone test – p=0.079). Nonetheless, we observed a subtle, 
though not significant, increase in mean thresholds for the control group in the S-Cone 
test, which could suggest differential eccentricity-related performance within the 
physiological range. 
Regarding the motion test, an interesting pattern was found. Ocular hypertensive 
subjects showed significantly varying performance with eccentricity (p=0.001). 
Moreover, this variation occurs in a linear fashion (p=0.001, partial eta-squared, 
  
 =0.605) meaning that visual performance is progressively impaired from the center to 
the periphery. However, in glaucoma subjects, there is a striking loss of significance in 
both mean differences (p=0.781) and linear trend (p=0.765) (see visual performance 
across eccentricities in Figure 5.2).  
In the achromatic contrast test, as in the motion test, a significant 
mean difference across eccentricities was only found in the ocular hypertensive group 
(p=0.049), yet the linear trend was only marginally significant (p=0.051,   
 =0.231) 
(eccentricity effect in Figure 5.2).  
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Figure 5.2. Visual performance across eccentricities (control, C; ocular hypertensive, HT; and glaucoma, 
G) for motion and achromatic contrast tests. A significant change across eccentricities was only found in 
the ocular hypertensive group for both tests with a linear trend clear and significant for motion tests and 
marginally significant for the achromatic contrast test, implying progressively more impaired visual 
performance from the center to the periphery. 
 
 
Concerning the L-Cone, M-Cone and S-Cone tests, significant mean differences 
were found in ocular hypertensive subjects (p=0.031, p=0.001 and p=0.009, 
respectively) and it was true for linear trends (L-Cone: p=0.009,   
 =0.371; M-Cone: 
p=0.001,   
 =0.601; S-Cone: p=0.003,   
 =0.467). The glaucoma group showed 
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significant mean difference across eccentricities only for L-Cone and S-Cone tests 
(p=0.004 and p=0.049, respectively) with a linear pattern (p=0.001,   
 =0.716 and 
p=0.014,   
 =0.504, respectively) (see Figure 5.3, task performance across different 
eccentricities).   
Given that none of the tests are comparing up vs down or left vs right (because 
reference and target and randomly swapped up and down or left right, in opposite 
hemifields), we do believe that meridian effects could only moderate the eccentricity 
effects into a small extent. 
 
 
 
Figure 5.3. Task performance across eccentricities (control, C; ocular hypertensive, HT; and glaucoma, 
G) for the L, M and S-cone tests. A significant mean difference and linear trend across eccentricities were 
found for both the ocular hypertensive and glaucoma groups in the L and S-cone tests and only for the 
ocular hypertensive group in the M-cone test. 
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ROC Curve – Sensitivity/Specificity analysis 
 
ROC curves were generated for all included tests, allowing to compare 
sensitivities at a fixed specificity. For control vs ocular hypertensive analysis, at 80% 
specificity, the highest sensitivity values (100%) were found for motion test at meridian 
135º, L-cone test at meridian 90º, M-cone test at meridians 45º and 135º, and S-cone 
test at meridian 90º (for more details see Table 5.1A). Achromatic contrast tests showed 
the lowest sensitivity values. In analysis by meridians, we found that meridian 0º (7.5º 
of eccentricity) showed, as expected, the lowest sensitivity values for all tests. 
For control vs glaucoma analysis, at 80% specificity, all tests reached 100% 
sensitivity, except for contrast test at meridian 0º (70% sensitivity). Whereas for ocular 
hypertensive vs glaucoma analysis, at 80% specificity, the highest sensitivity values 
(reaching 100%) were found for motion test at meridian 135º and contrast test at 
meridian 45º (for more details see Table 5.1B). 
 
 
Table 5.1. Areas under the receiver operating characteristic (ROC) curve (AUC) and associated 95% 
confidence interval (CI) are presented for motion, achromatic contrast and chromatic contrast (L-cone, M-
cone, S-cone) tests. Sensitivities obtained for each parameter at ~80% specificity, and criterion values 
used for that specificity are also presented for control vs ocular hypertensive (A) and ocular hypertensive 
vs gaucoma analysis (B). 
 
(A) 
Parameters AUC 95% CI p_value Sensitivity/ 
Specificity (%) 
Criteria for 
80% Specificity 
Motion test      
Meridian 0º 0.781 0.597, 0.909 0.0016 56/80 2.0052 
Meridian 90º 0.925 0.771, 0.988 <0.0001 87/80 1.3967 
Meridian 45º 0.965 0.828, 0.999 <0.0001 93/80 2.4319 
Meridian 135º 0.915 0.757, 0.984 <0.0001 100/80 1.6783 
Contrast test      
Meridian 0º 0.560 0.372, 0.737 n.s. 25/80 3.6252 
Meridian 90º 0.798 0.616, 0.920 0.0006 68/80 3.2027 
Meridian 45º 0.633 0.442, 0.798 n.s. 50/80 3.4585 
Meridian 135º 0.702 0.512, 0.852 0.0408 43/80 3.8624 
L-cone test      
Meridian 0º 0.794 0.611, 0.917 0.0004 62/80 0.0050 
Meridian 90º 0.898 0.736, 0.977 <0.0001 100/80 0.0031 
Meridian 45º 0.927 0.774, 0.989 <0.0001 93/80 0.0055 
Meridian 135º 0.904 0.744, 0.980 <0.0001 93/80 0.0056 
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M-cone test      
Meridian 0º 0.933 0.783, 0.991 <0.0001 93/80 0.0049 
Meridian 90º 0.948 0.803, 0.996 <0.0001 93/80 0.0056 
Meridian 45º 0.987 0.865, 1.000 <0.0001 100/80 0.0056 
Meridian 135º 0.992 0.872, 1.000 <0.0001 100/80 0.0054 
S-cone test      
Meridian 0º 0.904 0.744, 0.980 <0.0001 87/80 0.0557 
Meridian 90º 0.887 0.722, 0.972 <0.0001 100/80 0.0693 
Meridian 45º 0.929 0.777, 0.990 <0.0001 93/80 0.0707 
Meridian 135º 0.946 0.800, 0.995 <0.0001 87/80 0.0728 
 
 
 
(B) 
Parameters AUC 95% CI p_value Sensitivity/ 
Specificity (%) 
Criteria for 
80% Specificity 
Motion test      
Meridian 0º 0.931 0.760, 0.993 <0.0001 90/81 3.3387 
Meridian 90º 0.869 0.679, 0.968 <0.0001 80/81 4.0955 
Meridian 45º 0.847 0.652, 0.957 <0.0001 60/81 5.8459 
Meridian 135º 0.931 0.760, 0.993 <0.0001 100/81 4.6336 
Contrast test      
Meridian 0º 0.800 0.598, 0.930 0.0018 70/81 3.7594 
Meridian 90º 0.925 0.751, 0.991 <0.0001 90/81 5.4287 
Meridian 45º 0.978 0.830, 1.000 <0.0001 100/81 3.8624 
Meridian 135º 0.825 0.626, 0.945 0.0001 40/81 6.4971 
L-cone test      
Meridian 0º 0.869 0.679, 0.968 <0.0001 60/81 0.0074 
Meridian 90º 0.737 0.529, 0.889 0.0509 60/81 0.0087 
Meridian 45º 0.816 0.616, 0.939 0.0002 60/81 0.0095 
Meridian 135º 0.841 0.645, 0.953 0.0001 80/81 0.0095 
M-cone test      
Meridian 0º 0.844 0.648, 0.955 <0.0001 60/81 0.0134 
Meridian 90º 0.869 0.679, 0.968 <0.0001 80/81 0.0159 
Meridian 45º 0.894 0.710, 0.980 <0.0001 90/81 0.0159 
Meridian 135º 0.784 0.580, 0.920 0.0028 60/81 0.021 
S-cone test      
Meridian 0º 0.750 0.543, 0.897 0.0164 50/81 0.1338 
Meridian 90º 0.884 0.698, 0.975 <0.0001 70/81 0.1632 
Meridian 45º 0.869 0.679, 0.968 <0.0001 70/81 0.1932 
Meridian 135º 0.831 0.634, 0.948 0.0002 70/81 0.171 
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 Diagnostic accuracy by Areas Under the ROC Curve 
 
The AUC is an important measure that summarizes the diagnostic accuracy of 
each parameter. An AUC equal to 1 represents a perfect discrimination between groups, 
whereas an AUC of 0.5 represents chance discrimination.  
In control vs ocular hypertensive analysis, we found AUCs between 0.992 and 
0.560 (Table 5.1A; see also a representative example of ROC curve in Figure 5.4A). 
The parameters that showed higher AUC values (p<0.0001) were M-cone test at 
meridians 135º (AUC = 0.992), 45º (AUC = 0.987) and 90º (AUC = 0.948) and motion 
test at meridian 45º (AUC = 0.965). 
On the other hand, in ocular hypertensive vs glaucoma analysis (see a 
representative example of ROC curve in Figure 5.4B), we found AUCs between 0.978 
and 0.737. Motion test at meridians 0º (AUC = 0.931) and 135º (AUC = 0.931) and 
contrast test at meridians 90º (AUC = 0.925) and 45º (AUC = 0.978) showed the higher 
AUC values (p<0.0001) (see Table 5.1B). Whereas the AUC values were always higher 
than 0.900 for all tests, for control vs glaucoma analysis. 
 
 
 
Figure 5.4. ROC curves. Control vs ocular hypertensive (A) and ocular hypertensive vs glaucoma 
analysis (B) are represented by the test/meridian with higher AUC value: M-cone test at meridian 135º 
(A) and contrast test at meridian 45º (B). Sensitivity is plotted on the y-axis and “1-specificity” on the x-
axis.  
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5.5 DISCUSSION 
 
This study addressed patterns of damage in different stages along the natural 
history of glaucoma, as measured by L -, M -, S - cone contrast thresholds, motion 
discrimination and achromatic CS. For this purpose, we have used discrimination (in the 
sense of comparison across two locations) instead of detection tasks. However, since in 
the chromatic tasks a color signal had to be detected in one of the locations, it was in 
this sense a detection task (which was desired given the standard hardware used).  
Peripheral pairs of single dots, which were targets for motion, achromatic 
contrast and chromatic contrast discriminations, were used in order to isolate specific 
ganglion cell populations with a relatively small degree of redundancy (Wilson, 1970). 
Dots had constant local motion (except for direction and when speed was the dependent 
variable). Overall, this design optimized task difficulty, facilitated paradigm matching 
across tasks, and allowed us to test the visual system under low available information 
conditions (low redundancy). 
We have reasons to believe that our motion test also embed directional 
judgments. This is because if a 24 deg/s dot moves 9.6 degrees in the 400 ms trial, it 
will change direction about 4 times (since it is on a 2 degrees path moving back), 
whereas the reference dot (5 deg/s) will travel 2 degrees and therefore will not change 
direction. So, in addition to the speed discrimination, the detection of how often the dot 
changes direction is also informative. 
We found that impairment is concomitantly identified along all stages in motion, 
achromatic and chromatic channels. Moreover, sensitivity analysis showed that all tests 
discriminate well between early ocular hypertensive and the normal state, which is in 
line with our hypothesis that a smaller degree of test redundancy across pathways might 
allow for a greater diagnostic accuracy (Sample and Weinreb, 1990; Castelo-Branco et 
al., 2004; Fogagnolo et al., 2008). Concerning sensitivity analysis, and among the used 
psychophysical tests, motion (meridian 135º), L-cone (meridian 90º), M-cone 
(meridians 45º and 135º) and S-cone (meridian 90º) tests were quite sensitive to detect 
subtle damage at an early disease stage (ocular hypertension); unlike the achromatic 
contrast test, which showed the lowest sensitivity values and also the lowest diagnostic 
accuracy as measures by the area under the ROC curve. It is important to note that 
luminance noise used in chromatic S-, M- and L-cone tests ensured that the 
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measurement conditions were not biased (Castelo-Branco et al., 2004). On the other 
hand, the high discriminative power between the normal and hypertensive state is 
intriguing, given the fact that not all patients with well established ocular hypertension 
progress to the glaucomatous state (European Glaucoma Society, 2008). In fact, the 
conversion rate from untreated HT to glaucoma is only about 1% per year (Bach et al., 
2006). So, future studies using these psychophysical tests are necessary to get insight on 
the role of these methods as potential predictors of conversion of ocular hypertension to 
the glaucoma state, allowing treat only the future converters, preferably well before the 
glaucomatous field defects develop and avoiding unnecessary side effects and 
expenditure from treatment of nonconverters. 
Further, we found that psychophysical measures correlated significantly and 
strongly with the stage of the natural history of the disease, which suggest that each test 
at each meridian could be a potential marker of disease progression.  Under the 
conditions of our test, differences across patient groups were surprisingly larger when 
compared with differences found in other studies (Silva et al., 2010). 
On the other hand, since cell density redundancy is lower in the periphery for all 
pathways (Silveira and Perry, 1991), was expected that functional loss was more 
evident in the periphery, especially in early stages, such as in ocular hypertension. In 
fact, the eccentricity related patterns of damage with a significant linear trend for center 
versus peripheral decay were conspicuously observed in ocular hypertension and varied 
in a systematic manner across the natural history of the disease. This was particularly 
evident in the motion, achromatic contrast and M-cone tests that reveal clear a loss of 
these trends when progressing from the ocular hypertensive to the glaucoma stage. This 
finding is grounded on the hypothesis that with disease progression (in particular from 
ocular hypertension to glaucoma) there is a loss of central redundancy, weaning out the 
eccentricity-related asymmetries that were found on the ocular hypertensive group. This 
is particularly identifiable if visual tests are sufficiently sensitive. The model presented 
in Figure 5.5 attempts to explain the performance pattern found in motion, achromatic 
contrast and M-cone tests.  
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Figure 5.5. A theoretical model to explain visual performance asymmetries across disease stages, 
detected with sensitive testing conditions. The inner ring represents 7.5º of eccentricity, the middle ring 
10º and the outer ring 15º. With disease progression, visual performance is progressively impaired from 
the periphery (smaller redundancy) to the center (larger redundancy), thereby maximizing eccentricity 
related asymmetries in the ocular hypertension stage. In glaucoma, the loss of central redundancy weans 
out this asymmetry. 
 
 
Interestingly, concerning the L and S-cone tests, the linear trends found on the 
ocular hypertensive group were maintained in the glaucoma group. A possible 
explanation for these differences between the eccentricity related impairment patterns 
might be that with our tests we recruit different ganglion cells subsets from different 
visual channels, therefore probing visual performance at varying degrees of redundancy.  
In summary, our work proves that disease mechanisms evolve similarly in color, 
motion and achromatic pathways in the natural history of glaucoma. The promising 
sensitivity of test measures identified through ROC analysis and their diagnostic 
potential should be confirmed and generalized in future studies with larger samples. 
Eccentricity related patterns of damage across the natural history of the disease and the 
clear early peripheral decay pattern for ocular hypertension, suggests that a progressive 
pattern of loss of functional reserve (globally defined as the available pool of cells 
within a channel) can be measured along the natural history of glaucoma.  
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CHAPTER 6 
 
COMPARISON OF THE SENSITIVITY BETWEEN 
PSYCHOPHYSICAL, ELECTROPHYSIOLOGICAL AND 
STRUCTURAL TESTS IN ORDER TO DETECT EARLY DAMAGE IN 
OCULAR HYPERTENSION AND MONITOR GLAUCOMA 
PROGRESSION 
 
 
6.1 SUMMARY 
 
In this study we aimed to characterize early visual impairment of patients with 
HT, using psychophysical, electrophysiological and structural methods. We assessed the 
diagnostic accuracy of each test and compared their sensitivity for a fixed specificity. 
We also aimed to compare the sensitivity of these methods with three novel 
psychophysical discrimination tests designed by our group. The ability of these methods 
to probe disease progression was also analyzed.   
Visual function was assessed in a cohort of 52 participants recruited from the 
glaucoma consultation: 18 patients with HT, 15 glaucoma suspects and 19 with primary 
open-angle glaucoma. Quantitative psychophysical methods were used to assess magno 
(FDT), parvo and koniocellular pathways (CCT), and RGC function was assessed by 
PERG. Ganglion cells axonal layer thickness was also obtained using OCT. These 
patients were compared with an age-matched group of controls (n=20).  
An impairment in mean achromatic CS (p=0.0298) was found in patients with 
HT, as well as a reduced PERG N-95 wave amplitude (p=0.0499). Chromatic thresholds 
were significantly increased for protan, deutan and tritan axes (p<0.03) in these patients 
when compared with the control group. At approximately 80% specificity, the FDT 
showed the highest sensitivity to detect early functional damage (superior nasal 
quadrant, 66% sensitivity). We found a significant correlation between each test and 
ordered levels of disease progression (0.487<Rho<0.706, p<0.0001). The pattern of 
disease progression decline is approximately linear for all tests, but is more severe in 
OCT, namely RNFL thickness (  
  = 0.47). 
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We found a relative damage of magno, parvo and koniocellular retinocortical 
pathways since the initial stage of the disease. The sensitivity of the currently available 
tests used is this study is lower comparing with our novel psychophysical discrimination 
tools (sensitivity above 90% for 80% specificity), suggesting that their smaller degree of 
test redundancy leads to a great ability to detect early glaucomatous damage. Finally, all 
these tests are potential markers of disease progression, since their measures correlate 
moderately with the ordered levels corresponding to natural course of glaucoma, 
especially in which concerns the structural test since its the pattern of decline is more 
pronounced. 
 
 
 
6.2 INTRODUCTION 
 
Glaucoma is a progressive optic neuropathy characterized by gradual death or 
dysfunction of RGC with subsequent vision loss (Weinreb and Khaw, 2004; Anderson, 
2006). Traditional diagnostic approaches include criteria such as elevated IOP, visual 
field loss and optic nerve head atrophy. The elevated IOP is typically the dominant risk 
factor of the disease and current therapeutic strategies usually aim to reduce IOP as a 
way to slow vision loss, however many patients show a normal IOP and even when the 
IOP is well-controlled, disease progress may not be hindered (European Glaucoma 
Society, 2008). On the other hand, visual field loss does not appear at an early stage of 
the disease, meaning that when clinical features become evident in visual field testing 
(SAP), RGC loss can be as high as 50-60% (Harwerth et al., 1999; Harwerth and 
Quigley, 2006).  
Taking this into account, current diagnostic techniques do not allow an early 
diagnosis, therefore jeopardizing treatment success. Thus, due to the irreversible RGC 
loss in glaucoma, it is particularly important that new tests are introduced into clinical 
practice that enable detection of early defects at a pre-SAP stage. Some studies 
performed in patients with ocular hypertension, involving psychophysical and 
electrophysiological tasks have been conducted in this direction, in order to test their 
potential ability to detect early damage (Casson et al., 1993; Johnson et al., 1993; 
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Brusini and Brusatto, 1998; Landers et al., 2000; Sample et al., 2000; Castelo-Branco et 
al., 2004; Monhart, 2007; Cellini et al., 2012).  
To our knowledge, there are very few studies conducted in patients with ocular 
hypertension to evaluate the diagnostic accuracy of electrophysiological, 
psychophysical and structural tests simultaneously and their sensitivity to detect early 
changes (Bach et al., 2006). On the other hand, the ability of those functional and 
structural tests to monitor disease progression is often overlooked. 
We attempted to address this issue using a cohort of patients with ocular 
hypertension, the most recognized risk factor for developing glaucomatous damage 
(Bahrami, 2006; Coleman and Miglior, 2008; Kwon et al., 2009). We aim to 
characterized early visual impairment in these patients, by means of functional 
(psychophysical and electrophysiological) and structural methods, using sensitivity 
analysis. We also aimed to assess the ability of these methods to probe disease 
progression. Visual performance in the different stages of the disease within multiple 
visual channels (magno, parvo and koniocellular pathways), using computerized 
psychophysical tests that access the function of visual pathways in an independent 
manner was therefore also analysed. Finally, we wanted to compare the 
sensitivity/specificity of these methods with three novel two-alternative-forced-choice 
psychophysical discrimination tests (motion, achromatic and chromatic L, M and S cone 
contrasts) designed by our group, which probe distinct subsets of retinal ganglion cell 
populations. 
For this purpose, we used achromatic CS task using gratings with low spatial/ 
high temporal frequencies (probing magnocellular pathway) (Mateus et al., 2013; Silva 
et al., 2008), chromatic CS task using a static pattern of circles with a superimposed 
chromatic C-shaped ring (probing parvo and koniocellular pathways) (Castelo-Branco 
et al., 2004; Reis et al., 2012), an electrophysiological task assessing retinal ganglion 
cell (RGC) function (Reis et al., 2012) and optical coherence tomography to detect 
structural changes in peripapillary RCG axonal layer. 
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6.3 METHODS 
 
6.3.1 PARTICIPANTS 
 
The clinical sample consisted in 52 individuals recruited from the glaucoma 
consultation of the University Hospital of Coimbra: 18 patients diagnosed with ocular 
hypertension (HT; n = 18 eyes; mean age ± SD = 62.94 ± 7.38 years; VA = 0.83 ± 0.16; 
SAP MD = -1.00 ± 0.80; C/D diameter = 0.37 ± 0.08), 15 patients were glaucoma 
suspects (GS; n = 15 eyes; mean age ± SD = 65.36 ± 10.85 years; VA = 0.84 ± 0.14; 
SAP MD = -1.09 ± 0.89; C/D = 0.63 ± 0.07) and 19 patients with primary open-angle 
glaucoma (G; n = 19 eyes; mean age ± SD = 71.58 ± 11.48 years; VA = 0.74 ± 0.23; 
SAP MD = -10.07 ± 7.14; C/D = 0.71 ± 0.09). Patients were compared with an age-
matched group of controls (n = 20 eyes; mean age ± SD = 64.45 ± 8.41 years). Only the 
dominant eye of each subject was tested. ANOVA showed no significant age difference 
between groups.  
Patients with primary open-angle glaucoma fulfilled the following criteria: C/D 
vertical diameter of 0.5 or more, MD visual field global index less than -2 dB (or <5% 
of confidence interval). Glaucoma suspects had C/D of 0.5 or more and normal visual 
fields (MD more than -2 dB or >5%, of confidence interval). Patients with ocular 
hypertension showed an elevated IOP of 21 mmHg or more (on at least two occasions), 
without glaucomatous visual field defects (MD more than -2 dB or >5%, of confidence 
interval) or optic disc changes (C/D less than 0.5). 
All participants underwent a complete ophthalmic examination, including best 
corrected VA obtained with Snellen chart, Goldmann applanation tonometry (IOP 
measurement), slit lamp examination of the anterior segment, gonioscopy, retinal 
examination and optic disc evaluation. All individuals were also submitted to a visual 
field examination (white-on-white SAP) using the 30-2 standard program of Humphrey 
automated field analyzer (SITA-Fast strategy; HFA II, Carl Zeiss Meditec, Dublin, CA). 
Exclusion criteria included the following: neuro-ophthalmologic diseases, retinal 
diseases, diabetes even in the absence of retinopathy, VA less than 0.6, known color 
vision disorders, pseudophakic and aphakic eyes, significant media opacities that 
preclude fundus examination, central corneal thickness outside normal range (540 ± 30 
µm), and high ammetropy (sphere > ±4D; cylinder > ±2D). 
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Informed consent was obtained from all subjects, in strict accordance with the 
institutional guidelines and approval of our local ethics committee and after explanation 
of the objectives of the study. The research was conducted in accordance with the tenets 
of the Declaration of Helsinki. 
 
 
6.3.2 FUNCTIONAL ASSESSMENT 
 
In this study, participants performed the following psychophysical and 
electrophysiological methods: 
- Standard automated perimetry (Humphrey automated field analyzer, HFA II, 
Carl Zeiss Meditec, Dublin, CA); 
- Achromatic contrast sensitivity perimetry (FDT; Humphrey Matrix 
perimeter, Welch Allyn, Skaneateles, NY; Zeiss – Humphrey, Dublin, CA); 
- Chromatic contrast sensitivity psychophysical test (CCT; Cambridge 
Research Systems Lda., CRS, Rochester, UK); 
- Pattern electroretinogram (PERG; RETIport32, Roland Consult, Germany). 
 
 
6.3.3 STRUCTURAL ASSESSMENT 
 
We have used a Spectralis SD-OCT software version 5.3.2 (Heidelberg 
Engineering, Heidelberg, Germany) to obtain peripapillary RNFL measurements.  
 
 
For detailed methods see Chapter 3 – Methodological overview. 
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6.3.4 STATISTICAL ANALYSIS 
 
Statistical analysis was performed using SPSS statistical software package (IBM 
SPSS Statistics 21, IBM Corporation, NY, USA). After verifying the normality of the 
data across the study groups (Kolmogorov-Smirnov normality test and Levene 
homogeneity test), we applied a parametric analysis for overall means comparisons 
[multivariate analysis of variance (ANOVA)] and Fisher HSD post-hoc test for multiple 
comparisons. Spearman coefficient was used to correlate each quantitative test 
parameter and ordered subject grouping categories. When applicable, functional and 
structural data was fit with linear regression model and the adjusted coefficient of 
determination (  
 ) was used as an indicator of goodness of fit. 
To study the effect of eccentricity across achromatic contrast sensitivity channel, 
we used repeated measures ANOVA, with both main effects and linear trends adjusted 
to the least significant difference (LSD). We have also used a standard statistical 
measure of effect size (partial eta-squared,  
 
 ).  
The ROC curve analyses were performed using MedCalc version 12.2.1.0 
(MedCalc Software, Mariakerke, Belgium) to determine sensitivities at a fixed 
specificity (approximately 80%). Since the classification of patients was based on the 
results of SAP and optic nerve head excavation, these two parameters were not used to 
compare sensitivities. 
The relative diagnostic accuracies were assessed by comparing areas under the 
ROC curves (AUC). Results with p<0.05 were considered statistically significant. 
   
 
 
6.4 RESULTS 
 
Achromatic contrast sensitivity to probe Magnocellular pathway 
 
We found a significant group effect on mean contrast sensitivity [F(3,75) = 23.86, 
p<0.0001], mean deviation [F(3,75) = 20.22, p<0.0001] and pattern standard deviation 
[F(3,75) = 12.23, p<0.0001]. For MS and MD, post-hoc tests (corrected for multiple 
comparisons) revealed significant differences between all groups (p<0.04), except for 
HT vs GS (see Figure 6.1 and Figure 6.2A for a representative example); for PSD, post-
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hoc tests showed only significant differences between C and G (p<0.0001), HT and G 
(p<0.0001), GS and G (p=0.0001). 
Furthermore, a moderate correlation between MS and ordered subject grouping 
categories was found (MS: Rho = -0.542, p<0.0001), whereby CS performance declines 
with ordered levels of glaucoma progression. We also found moderate correlations 
between MD/PSD and clinical stages (MD: Rho = -0.585, p<0.0001; PSD: Rho = 0.510, 
p<0.0001). Then, we applied a linear regression to data to investigate the presence of 
linear trends and using this approximation found that mean CS decreases linearly 3.26 
dB per clinical stage [MS: y=33.26-3.26*clinical stage, F(1,77) = 52.87,   
  = 0.40, 
p<0.0001; MD: y=9.37-4.56*clinical stage, F(1,77) = 33.14,   
  = 0.39, p<0.0001; 
PSD: y=2.41+0.97*clinical stage, F(1,77) = 26.87,   
  = 0.25, p<0.0001].  
We also studied the effect of disease progression in terms of eccentricity and its 
loss was around 3.41/3.58 dB per clinical stage for the most central locations [Zone 1: 
y=35.95-3.41*clinical stage, F(1,77) = 39.25,   
  = 0.33, p<0.0001; Zone 2: y=34.89-
3.58*clinical stage, F(1,77) = 50.53,   
  = 0.39, p<0.0001] and was less pronounced in 
the most peripheral location, around 3.16 dB [Zone 3: y=32.60-3.16*clinical stage, 
F(1,77) = 48.95,   
  = 0.39, p<0.0001]. Along visual field quadrants, CS decreases 
between 2.94 dB and 3.77 dB per clinical stage [ST: y=33.65-3.77*clinical stage, 
F(1,77) = 61.19,   
  = 0.44; SN: y=33.01-3.33*clinical stage, F(1,77) = 35.74,   
  = 
0.31; IN: y=32.69-3.02*clinical stage, F(1,77) = 39.54,   
  = 0.33; IT: y=33.22-
2.94*clinical stage, F(1,77) = 37.40,   
  = 0.32; p<0.0001 for all cases]. 
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Figure 6.1. Achromatic contrast sensitivity, expressed in FDT global measures (MD – mean deviation; 
PSD – pattern standard deviation), along the disease progression stages (control, C; ocular hypertensive, 
HT; glaucoma suspect, GS; and glaucoma, G). Bars depict 10
th
 and 90
th
 percentiles, the top and bottom 
borders of the boxes represent the 25
th
 and 75
th
 percentiles, and the line segment inside the boxes depicts 
the median. 
 
 
 
Figure 6.2. FDT perimetry output (A), OCT – peripapillary RNFL thickness map (B) and PERG plots 
(C) of representative control, ocular hypertensive (#4) and glaucoma (#3) cases. Note the progressive 
impairment in all measures with disease progression, except for peripapillary RNFL thickness that 
showed no differences between the control subject and ocular hypertensive patient. 
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Chromatic contrast sensitivity to assess Parvo and Koniocellular pathways 
 
We found a significant group effect on chromatic CS for protan (red) [F(3,72) = 
4.485, p=0.0061], deutan (green) [F(3,72) = 4.401, p=0.0067] and tritan (blue) [F(3,72) = 
7.055, p=0.0003] cone confusion axes. Concerning post-hoc tests, we found significant 
differences between C and HT (p<0.03), C and G (p<0.001), HT and G (p<0.008), GS 
and G (p<0.02), for all chromatic axes (Figure 6.3). 
Using Spearman correlation analysis, a significant correlation between 
chromatic thresholds and ordered subject grouping categories was found (protan: Rho = 
0.598; deutan: Rho = 0.594; tritan: Rho = 0.658; p<0.0001). This means that chromatic 
thresholds increase with disease progression. Note that high chromatic thresholds relate 
to low CS. In this sense, through the linear regression analysis we found that chromatic 
thresholds increase linearly (corresponding to a contrast sensitivity decline) 37.86, 
38.96 and 51.63 u’v’ units per clinical stage, for protan, deutan and tritan axes, 
respectively [Protan: y=-3.84+37.86*clinical stage, F(1,74) = 10.22,   
  = 0.11, 
p=0.002; Deutan: y=-5.27+38.96*clinical stage, F(1,74) = 10.61,   
  = 0.11, p=0.0017; 
Tritan: y=4.31+51.63*clinical stage, F(1,74) = 18.10,   
  = 0.19, p<0.0001]. 
 
 
 
 
Figure 6.3. Chromatic contrast sensitivity performance over clinical stages (control, C; ocular 
hypertensive, HT; glaucoma suspect, GS; and glaucoma, G). Note that higher chromatic thresholds are 
related to lower contrast sensitivity.  
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Objective analysis of RGC axonal damage using Optical Coherence Tomography 
 
We found a significant effect of group on peripapillary RNFL thickness for 
superior [F(3,75) = 23.73, p<0.0001], inferior [F(3,75) = 23.25, p<0.0001], nasal [F(3,75) = 
12.59, p<0.0001] and temporal [F(3,75) = 19.97, p<0.0001] quadrants. Post-hoc tests 
showed significant differences between all clinical stages (p<0.04), except for C vs HT 
(p>0.05), for all tested RNFL quadrants (Figure 6.4; see also a representative example 
in Figure 6.2B). 
 We also found a significant correlation between RNFL thickness and ordered 
subject grouping categories (superior: Rho = -0.706; inferior: Rho = -0.649; nasal: Rho 
= -0.515; temporal: Rho = -0.655; p<0.0001), which means that peripapillary RNFL 
thickness decreases with the glaucoma progression. Thus, RNFL thickness decreases 
linearly with disease progression around 13.14 µm per clinical stage for superior 
quadrant [y=137.29-13.14*clinical stage, F(1,77) = 69.69,   
  = 0.47, p<0.0001], 15.06 
µm for inferior [y=152.09-15.06*clinical stage, F(1,77) = 64.48,   
  = 0.45, p<0.0001], 
7.11 µm for nasal [y=85.83-7.11*clinical stage, F(1,77) = 29.61,   
  = 0.27, p<0.0001] 
and 6.92 µm for temporal quadrants [y=78.70-6.92*clinical stage, F(1,77) = 54.59,   
  
= 0.41, p<0.0001]. 
 
 
 
Figure 6.4. Peripapillary RNFL thickness assessed by SD-OCT across disease progression stages 
(control, C; ocular hypertensive, HT; glaucoma suspect, GS; and glaucoma, G). 
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Macular ganglion cell function assessed by Pattern Electroretinogram 
 
We found a significant group effect on amplitudes of P-50 [F(3,67) = 7.67, 
p=0.0002] and N-95 [F(3,67) = 10.57, p<0.0001] waves. This effect was not verified for 
the implicit time of both waves, as well as N-95/P-50 ratio. Post-hoc tests for multiple 
comparisons revealed the following significant differences: P-50amplitude – C vs GS 
(p=0.0233), C vs G (p<0.0001), HT vs G (p=0.0025), GS vs G (p=0.0541); and for N-
95amplitude – C vs HT (p=0.0499), C vs GS (p=0.0005), C vs G (p<0.0001), HT vs G 
(p=0.0019) (see Figure 6.5 and a representative example in Figure 6.2C). 
 Spearman correlation analysis showed that P-50 and N-95 waves amplitudes 
decrease moderately with the disease progression (P-50 wave: Rho = -0.487; N-95 
wave: Rho = -0.524; p<0.0001). This amplitude decrease occurs in a linear fashion 
around 0.29 µV per clinical stage for the P-50 wave and 0.487 µV for the N-95 wave 
[P-50: y=2.71-0.29*clinical stage, F(1,69) = 23.20,   
  = 0.24, p<0.0001; N-95: y=3.75-
0.49*clinical stage, F(1,69) = 32.35,   
  = 0.31, p<0.0001]. 
 
 
 
Figure 6.5. Amplitude of P-50 and N-95 waves of pattern ERG over clinical stages (control, C; ocular 
hypertensive, HT; glaucoma suspect, GS; and glaucoma, G). 
 
 
Correlation analysis 
 
We found significant correlations between structural and functional measures 
specifically for the glaucoma group: 1) Peripapillary RNFL thickness (superior 
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quadrant) correlated positively with PERG N-95 wave amplitude (r=0.560, p=0.0115), 
FDT MD (r=0.640, p=0.0086), FDT Ring 1 (r=0.588, p=0.0195) and FDT Ring 2 
(r=0.547, p=0.0333); 2) Peripapillary RNFL thickness (inferior quadrant) correlated 
positively with FDT MD (r=0.514, p=0.0492) and FDT Ring 1 (r=0.537, p=0.0376). We 
also found a positive correlation between PERG N-95 wave amplitude and FDT in the 
inferior temporal quadrant (r=0.528, p=0.0419). These correlation patterns were not 
found in HT, GS and control groups. 
 
ROC Curve – Sensitivity/Specificity analysis 
 
ROC curves were generated for all tests in order to compare sensitivities at 
approximately 80% specificity. For control vs ocular hypertensive analysis, the highest 
sensitivity value was found for FDT SN quadrant (66%; cut-off: 26.6 dB), followed by 
CCT Protan (56%; cut-off: 59 u’v’ units) (for more details see Table 6.1A). 
Concerning ocular hypertensive vs glaucoma analysis, the highest sensitivity 
values were found for FDT ST quadrant (93%; cut-off: 22.75 dB), FDT Zone 2 (87%; 
cut-off: 23 dB) and CCT Tritan (84%; cut-off: 115 u’v’ units) (see Table 6.1B). On the 
other hand, for control vs glaucoma analysis, we found sensitivities higher than 80% (at 
approximately 80% specificity) for all parameters, except for PERG waves implicit time 
and ratio (around 20-30%).    
 
Diagnostic accuracy by Areas Under the ROC Curve  
 
In control vs ocular hypertensive analysis, we found AUC values between 0.777 
and 0.519. The higher AUC values correspond to CCT Protan (AUC = 0.777, 
p=0.0002), CCT Tritan (AUC = 0.729, p=0.0054) and also FDT IN quadrant (AUC = 
0.700, p=0.0190) (Table 6.1A). 
On the other hand, in ocular hypertensive vs glaucoma analysis we found AUC 
values between 0.924 and 0.506. In this sense, FDT ST quadrant (AUC = 0.924), OCT 
RNFL inferior (AUC = 0.901) and OCT RNFL superior (AUC = 0.883) showed the 
higher AUC values (p<0.0001) (see Table 6.1B). Concerning control vs glaucoma 
analysis, the parameter that showed the higher AUC was FDT MD (AUC = 0.971, 
p<0.0001). The AUC values were higher than 0.892 for all parameters (p<0.0001), 
except for PERG waves implicit time and ratio that represent only a change 
discrimination between groups (AUC values between 0.514 and 0.504).  
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Table 6.1. Areas under the receiver operating characteristic (ROC) curve (AUC) and associated 95% 
confidence interval (CI) are presented for psychophysical, electrophysiological and structural tests. 
Sensitivities obtained for each parameter at ~80% specificity, and criterion values used for that specificity 
are also presented [(A) Control vs Ocular hypertensive analysis; (B) Ocular hypertensive vs Glaucoma 
analysis]. 
 
(A) 
Parameters AUC 95% CI p_value Sensitivity/ 
Specificity (%) 
Criteria for 
80% Specificity 
FDT perimetry      
MS 0.684 0.537, 0.808 0.0307 44/81 26.63 
MD 0.694 0.547, 0.816 0.0253 50/81 -1.08 
PSD 0.597 0.449, 0.733 n.s. 28/81 4.34 
Zone 1 0.635 0.486, 0.766 n.s. 39/81 29 
Zone 2 0.629 0.481, 0.762 n.s. 39/81 27.25 
Zone 3 0.693 0.546, 0.815 0.0231 44/81 26.21 
ST quadrant 0.615 0.467, 0.750 n.s. 50/81 26.75 
SN quadrant 0.677 0.530, 0.802 0.0416 66/81 26.6 
IN quadrant 0.700 0.554, 0.821 0.0190 44/81 27 
IT quadrant 0.633 0.485, 0.765 n.s. 33/81 26.5 
Cambridge color test      
Protan 0.777 0.624, 0.889 0.0002 56/80 59 
Deutan 0.676 0.516, 0.810 0.0355 44/80 55.1 
Tritan 0.729 0.572, 0.853 0.0054 50/80 91.9 
OCT – RNFL thickness      
Superior 0.642 0.489, 0.770 n.s. 34/82 114 
Inferior 0.653 0.498, 0.787 n.s. 28/82 121 
Nasal 0.569 0.415, 0.714 n.s. 33/79 66 
Temporal 0.620 0.465, 0.759 n.s. 33/82 63 
PERG      
P-50 amplitude 0.663 0.491, 0.807 n.s 39/80 2.05 
N-95 amplitude 0.671 0.500, 0.814 0.0509 45/80 2.39 
P-50 implicit time 0.547 0.378, 0.709 n.s. 28/80 53 
N-95 implicit time 0.607 0.436, 0.761 n.s. 39/80 93 
N-95/P-50 ratio 0.519 0.352, 0.684 n.s. 22/80 1.06 
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(B) 
Parameters AUC 95% CI p_value Sensitivity/ 
Specificity (%) 
Criteria for 
80% Specificity 
FDT perimetry      
MS 0.841 0.672, 0.944 <0.0001 73/83 21.16 
MD 0.807 0.633, 0.923 0.0001 60/83 -5.09 
PSD 0.837 0.667, 0.942 <0.0001 67/83 4.85 
Zone 1 0.844 0.676, 0.947 <0.0001 80/83 26 
Zone 2 0.870 0.708, 0.961 <0.0001 87/83 23 
Zone 3 0.824 0.652, 0.934 <0.0001 67/83 20.29 
ST quadrante 0.924 0.777, 0.987 <0.0001 93/83 22.75 
SN quadrante 0.783 0.606, 0.907 0.0005 60/83 21.2 
IN quadrante 0.785 0.608, 0.908 0.0004 53/83 20 
IT quadrante 0.833 0.663, 0.940 <0.0001 73/83 23 
Cambridge color test      
Protan 0.814 0.652, 0.923 <0.0001 74/83 77 
Deutan 0.835 0.676, 0.936 <0.0001 68/83 79 
Tritan 0.857 0.702, 0.950 <0.0001 84/83 115 
OCT – RNFL thickness      
Superior 0.883 0.735, 0.965 <0.0001 74/83 102 
Inferior 0.901 0.757, 0.974 <0.0001 79/83 114 
Nasal 0.832 0.673, 0.934 <0.0001 68/83 61 
Temporal 0.851 0.695, 0.946 <0.0001 79/83 60 
PERG      
P-50 amplitude 0.754 0.585, 0.881 0.0017 53/83 1.14 
N-95 amplitude 0.754 0.585, 0.881 0.0018 53/83 1.74 
P-50 implicit time 0.506 0.337, 0.674 n.s. 37/83 56 
N-95 implicit time 0.601 0.427, 0.758 n.s. 26/83 96 
N-95/P-50 ratio 0.596 0.423, 0.754 n.s. 32/83 0.934 
 
Note: FDT = frequency doubling technology; MS = mean sensitivity; MD = mean deviation; PSD = 
pattern standard deviation; ST = superior temporal; SN = superior nasal; IN = inferior nasal; IT = inferior 
temporal; OCT = optical coherence tomography; RNFL = retinal nerve fiber layer; PERG = pattern 
electroretinogram; n.s. = not significant. 
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6.5 DISCUSSION 
 
In this study we have characterized the early visual impairment of patients with 
ocular hypertension, using psychophysical, electrophysiological and structural methods. 
We found changes in achromatic and chromatic contrast sensitivities and also in RGC 
function in the early stage of glaucomatous disease, corroborating the notion that 
functional damage may precede structural damage (Ventura et al., 2006). According, a 
significant correlation between structural and functional damage was found, but only in 
the later stages of the disease. Thus, a correspondence between structural and functional 
assessment may allow to establish with relative certainty the glaucomatous status. 
In this sense, visual performance seems to be impaired even before the 
appearance of visual field defects in standard automated perimetry (SAP) and also 
structural changes in optic nerve head and RNFL. This evidence is consistent with some 
previous studies in ocular hypertension, which use functional methods to indirectly 
assess specific RGC populations (Casson et al., 1993; Johnson et al., 1993; Brusini and 
Brusatto, 1998; Landers et al., 2000; Castelo-Branco et al., 2004; Bach et al., 2006; 
Cellini et al., 2012).  
We also found that functional and structural measures correlated significantly 
and moderately with the stage of the ordered clinical categories corresponding to the 
natural history of the disease, making these tests potential markers of disease 
progression. In general, the pattern of decline is approximately linear and is more 
pronounced for structural tests, namely RNFL thickness. About 47% of variability in 
RNFL thickness is explained by disease progression (  
  = 0.47), showing the role of 
this test in monitoring the progression of glaucoma. 
Visual performance within multiple visual channels was tested using a 
computerized chromatic contrast sensitivity test to probe parvo and koniocellular 
pathways and a FDT perimetry to probe magnocellular pathway (Silva et al., 2005; 
Ribeiro et al., 2012; Mateus et al., 2013). We found a relative damage of all 
retinocortical pathways since the initial hypertensive stage of the disease, proving that 
glaucoma is not restricted to impairment of M-cells (Kalloniatis et al., 1993; Felius et 
al., 1995; Greenstein et al., 1996; Alvarez et al., 1997; Castelo-Branco et al., 2004). 
Concerning ROC curve analyses, we found that FDT (superior nasal quadrant) 
showed the highest sensitivity value (66%) for 80% specificity. This perimetry uses 
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high temporal/ low spatial frequency stimuli, which functionally isolated a specific 
subgroup of magnocellular ganglion cells (My cells) (Quigley, 1998), increasing its 
sensitivity to detect glaucomatous defects before SAP. On the other hand, PERG waves 
amplitude showed a low sensitivity to detect early functional damage, which do not 
exceed 45% for 80% specificity, possibly due to this test study macular function, 
whereas the initial glaucomatous impairment appears in the peripheral visual field 
(Quigley, 2011). 
Interestingly, most of our novel psychophysical discrimination tests (see 
Chapter 3 – 3.1.1.4 Novel psychophysical motion, achromatic contrast and chromatic 
contrast discrimination tests), which were applied to a subgroup of glaucoma patients, 
showed a larger sensitivity to detect functional damage at the ocular hypertensive stage 
(above 90% for 80% specificity, reaching 100% in some cases). These novel tests 
exhibit a higher sensitivity when compared with the FDT, PERG and CCT, suggesting 
that a test with a smaller degree of redundancy across pathways enable for a greater 
diagnostic accuracy.  
In summary, the development of methodological approaches that can be used to 
detect glaucoma at an early stage of the disease is critical to prevent permanent 
structural damage and irreversible vision loss, not forgetting the fact that RGC 
dysfunction may precede their death. FDT and CCT Protan performed well in detecting 
early glaucomatous damage in a cohort of patients with ocular hypertension, whereas 
longitudinal analysis of the ganglion cells axonal layer appears to be a good method to 
monitor the progression of the glaucomatous disease.  
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CHAPTER 7 
 
DISCUSSION AND CONCLUSIONS 
 
 
7.1 NOVEL BIOMARKERS OF PATHOPHYSIOLOGICAL 
IMPAIRMENT IN ACQUIRED AND GENETIC DISEASES OF 
RETINAL GANGLION CELL DYSFUNCTION: ANALYSIS 
BETWEEN AND WITHIN CONDITIONS  
 
 In this study, we attempted to identify novel biomarkers of pathophysiological 
impairment in two distinct disease models of RGC dysfunction. For this purpose, we 
addressed an acquired and an inherited disease, namely glaucomatous optic neuropathy 
and LHON, respectively. While in glaucomatous optic neuropathy functional tests seem 
to have a higher sensitivity (and larger area under the ROC curve) in detecting changes 
the initial stage of the pathology (ocular hypertension stage), in Leber optic neuropathy 
we found that structural tests were more sensitive in determining the presence of LHON 
carriers status. 
For both optic neuropathies, the CCT protan seems to be the chromatic axis that 
best discriminate between normal and pathological status, as demonstrated by the higher 
AUC and higher sensitivity for 80% specificity when compared with deutan and tritan 
axes.  
On the other hand, PERG showed a higher diagnostic accuracy in LHON 
carriers as compared with patients with ocular hypertension, albeit still showing in 
general lower performance than the other low-level tests. This evidence is consistent 
with the fact that electrophysiological test allow to assess the macular function, whereas 
the initial glaucomatous damage appears in the peripheral visual field and our LHON 
carriers showed a constant pattern of a paracentral defect in visual field with a preserved 
sensitivity of the central locations. 
 
Concerning acquired optic neuropathy model, ROC curve analysis showed that 
FDT perimetry, which uses sinusoidal grating stimulus with high temporal and low 
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spatial frequencies optimized to activate the magnocellular pathway, exhibited the 
highest sensitivity value for a 80% specificity level. Indeed, we found that FDT 
perimetry can detect functional deficits even before visual field defects arise in standard 
white/white perimetry and optic nerve changes become evident, showing the important 
role of this psychophysical test in the early stage of glaucomatous disease.  
Comparing currently available psychophysical and electrophysiological tests 
with the three novel psychophysical tools developed by our group, we found that the 
novel tests showed a larger sensitivity to detect functional damage at the ocular 
hypertensive stage, proving that a smaller degree of functional test redundancy across 
pathways might allow for a greater diagnostic accuracy. The novel 2AFC 
psychophysical tests required the comparison and discrimination of a visual feature 
(motion, achromatic contrast and chromatic contrast) between two separated moving 
single dots, which were presented in opposite hemifields. We found that these novel 
discrimination tests reach near 100% sensitivity for 80% specificity in some cases, 
namely motion (meridian 135º), L-cone (meridian 90º), M-cone (oblique meridians) and 
S-cones (meridian 90º) tests. The parameter that showed lower sensitivity values was 
the achromatic contrast test, however still within the same performance level as the 
currently available tests. 
Further, we found that functional and structural measures correlated significantly 
and strongly with the ordered stages of the natural history of the disease, which suggest 
that each test could be a potential marker of disease progression.   
The fact that we have applied a significant range of psychophysical chromatic, 
achromatic and motion tests allowed us to study independent visual information 
processing across magno, parvo and koniocellular pathways. We found a relative 
damage of all retinocortical channels since the early stages of glaucomatous disease. 
 
Regarding the ROC curve analysis for the genetic optic neuropathy model, we 
found that the most peripheral ring of macular RNFL thickness showed the larger AUC 
value and was the most sensitive classifier of the mutation status, suggesting an 
important role in pre-clinical phases. This is consistent with the known vulnerability of 
small axons of papillomacular bundle in the asymptomatic stage of this disease. The 
preferential involvement of the papillomacular bundle is probably due to the particularly 
disadvantageous energetic conditions intrinsic to the small and less myelinated axons 
that constitute the macular RGC.   
Pathophysiological mechanisms and novel biomarkers in acquired and genetic diseases of the RGC 
 
- 105 - 
 
We also found that cortical measures (especially extrastriate) discriminate well 
between healthy and mutation carriers, at the performance level of some of the retinal 
outcomes, suggesting that cortical and retinal markers are highly coupled in the 
determination of LHON carrier status. 
Interestingly we found a link between the most discriminative feature of RGC 
impairment (macular RNFL) and cortical reorganization in LHON carriers, as assessed 
by cortical thickness measures in retinotopically mapped visual cortical areas. This is 
consistent with the idea that structural plasticity can occur even during clinically silent 
degeneration of RGC, and importantly, in the presence of relative peripheral visual loss, 
although retinotopic maps are still intact. 
 
 
 
7.2 FUTURE WORK 
 
Since only a small percentage of patients with ocular hypertension progress to a 
more advanced stage of the disease, future studies with larger samples are necessary to 
get insight on the role of these methods as potential predictors of conversion of ocular 
hypertensive to the glaucoma state. In this way, we might also avoid unnecessarily 
treatment of patients who would never convert to glaucoma stage. On the other hand, it 
would be possible focus our attention on patients who actually require treatment, 
allowing to treat future converters before a significant number of RGC being 
irreversibly damage. 
Concerning LHON carriers, a follow-up of these patients should be done 
periodically to check how the structure and function of RGC behave along the 
preclinical phase until conversion to the symptomatic cell death stage. It would be also 
interesting to follow the changes in cortical thickness in these patients over preclinical 
period until conversion to clinical stage, since this approach has never been done before 
in LHON groups. 
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